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1 Introduction 
With the rapid development of industrialization, environmental pollution has 
become a global concern. The chemical industry and other related industries supply a 
huge variety of essential products, from petroleum to pharmaceuticals. However, these 
manufacturing processes also lead to millions of tons of waste, which have the potential 
to be harmful to the environment, human health and to all living species (Clark 1999). 
Green chemistry has become a worldwide approach that leads to design and manufacture 
of cost-competitive chemical products and processes to reduce or to eliminate the use and 
generation of substances hazardous to human health and environment (Chanshetti 2014). 
Enzymes can replace chemo-catalysts in synthetic routes and enable new synthetic 
pathways, which may be shorter, more efficient and more sustainable. Moreover, 
combining chemo- and bio-catalysis generates opportunities for the design of new 
synthetic routes (Bornscheuer et al. 2012; Choi et al. 2015; Truppo 2017). Due to their 
ability to catalyze important synthetic chemical reactions under mild conditions compared 
with chemical catalysts that need harsher conditions, such as high temperature and 
pressure, enzymes became important tools in the industrial synthesis of pharmaceutical, 
cosmetic, food and bulk chemicals. What is more, enzymes are biodegradable and have 
nontoxic nature, which makes them good alternatives to hazardous chemical pollutants 
(Singh et al. 2016; Timson 2019). However, the number of applications of enzymes is 
limited because of the enzyme availability, substrate scope, and operational stability. 
Recent scientific breakthroughs in genomics, directed protein evolution and technology 
advances as bioinformatic tools should help to overcome these limitations. Worldwide, 
the challenge for chemists is to develop synthetic methodology and „green” processes that 
posess environmental and economic benefits, which are now required as: reduction of 
materials and energy intensity of chemical processes and by-products, minimization or 
elimination of harmful chemicals emission in the environment (Schmid et al. 2001; 
Thomas et al. 2002; Singh et al. 2016). The biocatalytic transformations have been 
employed in industries and medicine for the sake of development of new production 
routes to fine chemicals, pharmaceutical ingredients and precursors, agrochemicals, and 
even bulk commodities. Figure 1 summarizes several applications of enzymes based on 
different industrial sectors. Due to this versatility of applications, enzymes can be 
considered as a powerful technology for a biobased economy (Wohlgemuth 2009). 
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Figure 1:Industrial applications of microbial enzymes. Data adapted from Singh et al. 2016.(Singh et al. 
2016) 
 
For the majority of enzyme classes, almost 75% of all industrial enzymes are 
hydrolytic enzymes. Alcohol dehydrogenase, amylases, cellulases, lipases, 
ketoreductases, proteases and xylanases, dominate the enzyme market, accounting for 
more than 70% of all enzyme sales (Bornscheuer et al. 2012; Li et al. 2012; Singh et al. 
2016; Buller et al. 2017). 
Over the last decades, oxidoreductases have been more regularly taken into 
account in the design of novel process routes (e.g., alcohol dehydrogenases, BVMOs, 
ketoreductases, laccases, peroxidases) whereas a few lyases (e.g., pectate lyase for raw 
cotton bio scouring, pectin lyase for the food industry) have been commercially 
introduced but have not yet been sufficiently developed to become widely applicable in 
manufacturing (Galante and Formantici 2005; Kirschner and Bornscheuer 2008; Kashyap 
and Mishra 2011; Bornscheuer et al. 2012; Staudt et al. 2013; Patel et al. 2016; Buller et 
al. 2017; Zhao et al. 2018; Atalla et al. 2019). Diverse industries demand the discovery 
and application of novel enzymes. Today, advances in microbial genome engineering 
techniques allow the easy modification of genes in the biosynthesis pathway to maximize 
the production of high-value molecules in the host. 
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In particlular, hydroxylated compounds are of great value, but selective 
hydroxylation of organic molecules is a challenge in the classical organic chemistry. 
Therefore, enzymes which catalyse selective hydroxylation are highly needed.  
Since oxidoreductases, more precisely P450 monooxygenases, can perform 
selective hydroxylation of non-activated carbons, they are a class of enzymes with 
potential in the production of a variety of fine chemicals and pharmaceuticals (Martínez 
et al. 2017). 
Lyases are excellent candidates for the commercial production of optically active 
compounds. Lyases catalyze the cleavage or formation of C-C, C-N, C-O and other bonds 
to yield double bonds. They also catalyze the addition of groups to double bonds. 
Moreover, they do not require (expensive) cofactors and give an absolute stereospecificity 
with a theoretical yield of 100%, which is much more efficient compared to enantiomeric 
resolutions of only 50% productive rate. Therefore, lyases are attracting considerable 
interest as biocatalysts for the production of optically active compounds. Lyases such as 
hydroxynitril lyase, aspartase, nitrile hydratase, pyruvate decarboxylases have already 
found application in a few large commercial processes (van der Werf et al. 1994; Mahdi 
and Kelly 2008). 
Moreover, industry demands the discovery of more selective and efficient novel 
catalysts and processes for the manufacture of phosphorylated, enantiomerically pure fine 
chemicals and metabolites. The synthesis and analysis of phosphorylated metabolites, 
which play a central role in metabolism, signaling, regulation and maintenance, is still of 
major interest today. Therefore, synthetic methodologies for the phosphorylation of small 
molecules continue to be important. While chemical synthesis of these small molecules is 
challenging and requires the use of protecting groups, biocatalytic phosphorylation can be 
highly site-selective and does not need protecting groups. A large number of 
phosphorylases, phosphatases, and phosphotransfer-kinases have been described as 
enzymes for the biocatalytic synthesis of phosphorylated metabolites. Therefore, 
employing kinases in the industrial biocatalytic production of phosphorylated metabolites 
would be highly beneficial (Wohlgemuth 2017; Wohlgemuth et al. 2017; Roy et al. 
2019).  
Taking into consideration the above arguments, the objective of this thesis was to 
achieve efficient, selective and environmentally friendly processes, which enable 
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obtaining bioactive compounds such as metabolites and fine chemicals using diverse 
classes of enzymes such as P450 monooxygenases, lyases and kinases. 
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1.1 Enzymes in organic synthesis  
Because of the unique properties of enzymes, such as high regio-, chemo- and 
stereoselectivity, fast action, and their environmentally friendly character, enzymes are 
used in many industries. According to the type of the catalyzed reaction, enzymes can be 
classified into seven types (Figure 2). There are many commercially potencially useful 
microbial enzymes in the metagenomic database, but as of today, 75% of the industrial 
enzymes are hydrolytic enzymes (Li et al. 2012). In this thesis, the oxidoreductases, 
tansferases and lyases will be detailed and their scope of industrial application will be 
discussed (indicated in green in Figure 2). 
 
Figure 2: Systematic name is given according to the reaction in the seven classes of the enzymes. 
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1.2 Oxidoreductases: P450-monooxygenases 
Oxidoreductases are a broad class of enzymes that catalyze biological 
oxidation/reduction processes. The main reason for the interest in oxidoreductases and 
their industrial application is their ability to catalyze regio-, chemo-, and stereoselective 
reactions where chemical catalysts often fail. Therefore, oxidoreductases are often 
considered as a perfect tool for green chemistry and have already several applications in 
the industry ( e.g. the synthesis of products such as cis-dihydrodiols, catechols, epoxides) 
(May and Padgette 1983; May 1999; Xu 2005; Nolan and O’Connor 2008; Martínez et al. 
2017). Oxygenases belong to the oxidoreductase class of enzymes, which introduce one 
(monooxygenases, e.g. P450, BVMO) or two (dioxygenases, e.g. toluene dioxygenase, 
naphthalene dioxygenase) oxygen atoms into their substrates. Typically NADH or 
NADPH serve as reduction equivalents through electron transfer proteins (such as 
reductase) (Williams et al. 1990; Lee 2006; de Souza et al. 2017).  
The cytochromes P450 monooxygenases constitute a large family of cysteinato-
heme enzymes. In all these enzymes, the prosthetic group is constituted of iron(III) 
protoporphyrin IX covalently linked to the protein by the sulfur atom of a proximal 
cysteine ligand (Guengerich and Munro 2013; Munro et al. 2013). They are b-type 
hemoproteins, and they owe their name to the intense light absorption at 450 nm from 
their unusual spectral properties displaying a typical absorption at maximum 450 nm of 
the reduced CO-bound heme-complex. They play a key role in the oxidative 
transformation of endogenous and exogenous molecules. As the means of oxidation, P450 
uses molecular oxygen, introducing one atom of oxygen into the substrate and reduces the 
second oxygen to a water molecule, utilizing two electrons derived from the cofactors 
NADH or NADPH and transfer them to the heme iron of the P450 (Equation 1)(Meunier 
et al. 2004; Urlacher and Girhard 2012; Erdogan 2019). 
 
RH + O2+ NAD(P)H + H
+→ ROH + NAD(P)+ + H2O 
Equation 1: General reaction of P450-monooxygenase-catalyzed reactions.  
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1.2.1 Catalytic cycle of cytochrome P450 enzymes 
The catalytic cycle of a typical P450 is shown in Figure 3.I.  
 
 
Figure 3.I: Scheme of the catalytic cycle of cytochrome P450 monooxygenases. The ‘uncoupling pathways’ 
are shown with dotted lines. 3.II: Scheme of the ‘oxygen rebound’ mechanism. The ferryl-oxo intermediate 
(CpdI) is considered to be the active oxidant that abstracts hydrogen from the substrate (R-H), which is 
followed by quick radical recombination and release of the oxygenated (frequently hydroxylated) product 
(R-OH) Adapted from Munro et al. (2013) (Munro et al. 2013). 
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The P450 cycle begins with the heme in the resting form (1) and shows successive 
events of substrate (RH) binding (2) with distal water ligand dissociation. Substrate 
binding induces electron transfer from NAD(P)H via cytochrome P450 reductase or 
another associated reductase (3). Molecular oxygen binds to the ferrous heme center to 
form a ferric peroxo state (4); next a second electron is transferred from either 
cytochrome P450 reductase, ferredoxins or cytochrome b5, reducing the Fe-O2 adduct to 
give a short-lived peroxo state (5a). The peroxo group is rapidly protonated to generate 
the transient compound 0 (ferric hydroperoxo) species (5b). Further protonation of this 
intermediate leads to a release of one water molecule and forming of the highly reactive 
species referred to as P450 Compound I. These are used as the catalyst for oxygen 
insertion (6) to generate ROH product (7). The final step is a dissociation of the oxidized 
substrate from the active site of CYP, wherein the enzyme returns to its initial ferric state 
(Fe
3+
) and is thus equipped to react again. The oxygen rebound mechanism (hydroxylated 
product formation and release) is shown in Figure. 3.II (under the catalytic cycle of 
P450). Hydrogen abstraction from the substrate takes place by compound I (6) to form 
compound II (6a), prior to rebound of the hydroxyl to the substrate radical to form the 
hydroxylated product (Werck-Reichhart and Feyereisen 2000; Isin and Guengerich 2008; 
Munro et al. 2013; Dubey and Shaik 2019). 
The normal reaction mechanism of cytochrome P450 operates by utilizing two 
reducing equivalents to deplete atmospheric dioxygen, producing one molecule of water 
and an oxygenated product in an overall stoichiometry of 2 electrons:1 dioxygen:1 
product (Grinkova et al. 2013). Often, electrons generated by the redox partner, are not 
transferred effectively. Therefore, the catalytic cycle may be hindered in some cases by 
three so called “uncoupling” pathways (depicted by dotted lines in Figure 3), yielding 
hydrogen peroxide or superoxide anion without substrate metabolism. The first is the 
“oxidase shunt” pathway, where Compound I (6) is protonated and reduced to produce a 
water molecule. The alternative route for monooxygenation is via the “peroxide shunt”, 
interaction with single-oxygen donors such as H2O2 or related oxygen donors, which leads 
to the formation of the iron-oxo intermediate (compound 0 (5b), from the ferric substrate-
bound form (2). Interestingly, it has been shown that there are a few examples of P450s 
(P450 peroxygenases) that are able to use hydrogen peroxide for their benefit and drive 
the reverse reaction, generating Compound 0 (5b) directly from the initially substrate-
bound (2) intermediate (Makris et al. 2005). The third uncoupling pathway is the 
“autooxidation shunt” path, where the ferric-superoxy complex (4) produces a superoxide 
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anion and the enzyme returns to the resting state (2). The formation of reactive oxygen 
species (uncoupling) is an unfavorable side reaction (Morlock et al. 2018). The coupling 
efficiency is a measure of the number of electrons donated from NAD(P)H, which are 
successfully used for the catalysis of a bound organic substrate (Albertolle and Peter 
Guengerich 2018). Whereas uncoupling can lead to inactivation of the enzyme, the 
coupling efficiency of a P450 is an important determinant of the enzymes rate of 
catalysis. The coupling efficiency is a measure of the number of electrons donated from 
NAD(P)H, which are successfully used for the catalysis of a bound organic substrate 
(Cook et al. 2016). It has been shown in the past that the bacterial P450 has higher 
coupling efficiencies for native substrates compared to mammalian (Albertolle and Peter 
Guengerich 2018). Moreover, for self-sufficient systems like the cytochrome P450 BM3, 
the coupling efficiency can be 100% (Ciaramella et al. 2017), whereas for other P450 
multi-component systems, the coupling efficiency can be very low (0.5–3%) (Gruenke et 
al. 1995). For instance, BM3, which acts as a fatty acids oxygenase displaying a high 
activity (>1000 turnovers/min), has a coupling efficiency nearly 100%, meaning that all 
electrons donated from the nicotinamide cofactor are used for catalysis (Ciaramella et al. 
2017). Moreover, different mutants of P450 BM3 have a coupling efficiency against 
testosterone rangeing from 13.5% to 83.5% (Ciaramella et al. 2017).  
1.2.2 Classification of cytochrome P450 enzymes 
Depending on structural characteristics and their type of redox partners, P450s can 
be classified according to their number of component systems: single-, two- or three 
protein systems. Prokaryotic P450s are generally three-component systems, whereas 
eukaryotic P450s like hepatic P450s and many plant and fungal P450s are working as two 
component systems. There are also self-sufficient isozymes, where the heme and 
reductase domains are fused. According to Hannemann et al., depending on the reductase, 
cytochrome P450 systems can be divided into at least ten different classes (Figure 
4)(Hannemann et al. 2007). 
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Figure 4: Scheme showing the different cytochrome P450 classes, further described in section 1.1.2  
Adapted from Hannemann et al. (2007). 
 
Class I contains most of the known bacterial P450s and also a number of 
eukaryotic mitochondrial systems (Figure 4, A and B respectively). All these systems are 
comprised of three separate proteins: the FAD-dependent ferredoxin reductase (FdR) that 
transfers the electrons from NADH or NADPH to the ferredoxin (Fdx) (containing an 
iron–sulfur cluster), which provides the reducing equivalents to the P450 heme domain. 
In the bacterial systems, all three proteins are soluble (Figure 4A). In eukaryotes though, 
only the ferredoxin is a soluble protein, while the reductase is membrane-associated and 
the cytochrome P450 is incorporated in the mitochondrial membrane (Figure 4B). 
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Examples of class I P450s are P450cam from Pseudomonas putida (bacterial system) and 
CYP11A1 (P450scc) (mitochondrial eukaryotic system) (Hannemann et al. 2007). 
The Class II system, most commonly found in eukaryotes, contains two integral 
membrane proteins (Figure 4C): the cytochrome P450 and the NADPH- cytochrome 
P450 reductase (CPR). CPR contains the prosthetic groups FAD and FMN, which transfer 
both required redox equivalents from NADPH to one of the isoforms of cytochrome 
P450. 
The Class III system was reported for the first time by Hawkes et al in 2002 
(Hawkes et al. 2002). This class is similar to the bacterial Class I (Figure 4D), when it 
comes to comprising three separate proteins, a FAD-dependent ferredoxin reductase, a 
small intermediate redox protein (Fldx) and P450. The difference, however, is that the 
Class III systems utilize an FMN-dependent redox protein referred to as flavodoxin 
(Fldx), rather than the iron–sulfur cluster containing Class I-type ferredoxin (Fdx) (Cook 
et al. 2016). An example of Class III P450s is P450cin from Citrobacter braakii. 
The Class IV is the only class of P450, which has been shown to utilize redox 
partners specific for an electron donor different than NAD(P)H. Namely, the reductase 
system obtains electrons from pyruvic acid rather than from NAD(P)H (Figure 4E). 
Example of Class IV was identified by investigating the first thermophilic CYP119 from 
the extreme acidothermophilic archaeon Sulfolobus solfataricus(Park et al. 2002; 
Hannemann et al. 2007). 
In Class V, in contrast to the classical three-component Class I system, P450 
includes two components: a NAD(P)H-dependent reductase (Fdr) and a P450 domain 
bound to C-terminal ferredoxin (Fdx) via an alanine-rich linker region, which acts as a 
flexible hinge allowing interactions between the two domains (Figure 4F). A member of 
this class was described for the first time by Jacson et.al. in 2002 (Jackson et al. 2002). 
The Class VI system  (Figure 4G) is similar to class V, but the C-terminal-bound 
ferredoxin (Fdx) is replaced with an N-terminal-bound flavodoxin (Fldx)(Cook et al. 
2016). 
The P450 Class VII (Figure 4H) presents a completely novel domain architecture: 
the P450 domain is C-terminally bound to phthalate dioxygenase reductase domain 
(PFOR). It has three distinct domains: an NADH-binding domain, an FMN-binding 
domain and an Fdx domain containing an iron-sulfur cluster. The member of Class VII 
was reported for the first time by Roberts et al. in 2002 and named as P450RhF (Roberts 
et al. 2002). 
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As the monooxygenases, members of Class VIII are catalytically self-sufficient. 
This means that P450 domain is fused to a eukaryotic-like diflavin reductase partner – 
cytochrome P450 reductase (CPR) – in a single polypeptide chain (Figure 4I) (Cook et al. 
2016). The most intensively studied member of this class is the BM3 (CYP102A1) from 
Bacillus megaterium (Fulco and Miura 1974). 
The Class IX systems (Figure 4J) are unique since they require no redox protein 
partners for transfer of electrons from NAD(P)H and consist solely of nitric oxide (NO) 
reductases. A member of this class was described for the first time in the filamentous 
fungus Fusarium oxysporum (Kizawa et al. 1991). 
Class X consists of cytochrome P450 enzymes, which do not require the transport 
of electrons via redox proteins but use differing intramolecular transfer systems instead 
(they require neither O2 nor NAD(P)H) (Figure 3K). Members of Class X P450 utilize the 
acyl hydroperoxide groups of their substrates as oxygen donors to form a new carbon-
oxygen bond (Hannemann et al. 2007; Cook et al. 2016). 
1.2.3 Biotechnological application of Cytochromes P450 
P450 monooxygenases catalyze the hydroxylation or epoxidation of non-activated 
carbon atoms with high selectivity. They act on a broad range of chemically diverse 
substrates like fatty acids, alkanes, or monoterpenes to yield vitamins, steroids, 
antibiotics, diverse drugs and xenobiotics. Moreover, they have shown great potential in 
bioremediation, which makes them promising candidates in biotechnological applications 
(Figure 5) (Bernhardt 2006; Bhattacharya and Yadav 2017; Urlacher and Girhard 2019).  
Despite this potential of P450 enzymes, industrial application of those enzymes is 
often limited by widely recognized technical bottlenecks. Lack of stability, low activity, 
narrow substrate specificity, expensive cofactor requirements, solvent tolerance and 
limitations in the electron transfer and electron supply are some of the main reasons why 
the industrial application of this enzyme system is challenging. Alternately, use of a 
whole-cell system allows to overcome some of these limitations providing a cofactor 
regeneration system (co-expression of redox partners) and a protected environment to 
enhance the stability of the biocatalyst (Urlacher and Girhard 2011; Bracco et al. 2013a; 
Lundemo et al. 2015).  
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Figure 5: Examples for substrates of P450 monooxygenases: CYP2B6 was shown to catalyse the side chain 
oxidation of styrene (Nakajima et al. 1994); members of the CYP3, CYP7, CYP8, CYP27, CYP39, and 
CYP46 families CYP7A1, CYP7B1, and CYP39A1 initiate the synthesis of bile acids from cholesterol 
(Nebert and Russell 2002); BM3 oxidizing indole (Li et al. 2005); CYP105A1, catalyzes a three-step 
hydroxylation of vitamin D3 (Hayashi et al. 2010); BM3 mutant (containing 11 mutations), catalyse 
hydroxylation of a range of alkanes from octane through to propane, including cyclohexane (Butler et al. 
2013); BM3 CYP505 catalyse hydroxylation of fatty acids (Boddupalli et al. 1992; Kitazume et al. 2002); a 
new member of the CYP116B subfamily—P450LaMO oxidize linalool (Yin et al. 2014); CYP members of 
P. placenta (CYP5150, CYP5027, and CYP5350) are involved in the oxidation of a series of PAHs such as 
anthracene, carbazole, phenanthrene, and pyrene (Ide et al. 2012); CYP107DY1 show catalytic activity 
towards mevastatin (Milhim et al. 2016); CYP3A4 catalyse hydroxylation of LCA (Araya and Wikvall 
1999); a BM3 mutant exhibited activity with the steroid derivative trimethyl estriol (Lewis et al. 2010). 
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1.2.4 Hydroxylation of steroid molecules such as the bile acids using 
P450 monooxygenase CYP107D1(OleP) from Streptomyces 
antibioticus 
In mammals, cholesterol provides essential building blocks for the synthesis of 
vitamin D and steroid hormones, yet most of the cholesterol is converted to bile acids 
(BAs). Bile acids and steroid hormones of higher vertebrates differ strongly in the shape 
of their ring structures. While bile acids have the 5β-steroid structure in common, also 
known as the 5β-cholane scaffold, steroid hormones possess the 5α-steroid structure, 
making the ring system of the 5α-steroids flatter than that of the 5β-steroids. BAs can take 
over various roles in the human body; they can, e.g. act as emulsifiers of lipid aggregates 
or transporters of lipids, function as hormones in cholesterol biosynthesis or promote liver 
regeneration (Russell 2009; Wang et al. 2013).  
Yet, bile acids are also suspected of acting as potential carcinogens and have been 
linked to liver cancer. Especially secondary bile acids, which result from bacterial 
biotransformations in the colon, have been associated with gastrointestinal cancers 
(Bernstein et al. 2005; Wang et al. 2013; Ajouz et al. 2014; Ridlon et al. 2015). Therefore, 
bile acids became attractive therapeutic targets for metabolic disorders (Trauner et al. 
2010; Li and Apte 2015; Takahashi et al. 2016). Many bacterial P450s are known, which 
can convert steroid hormones regio- and stereo-selectively. However, the knowledge of 
bacterial P450s, which can selectively convert bile acids, is scarce (Anzenbacher and 
Anzenbacherová 2001). Hydroxylation of bile acids on the 6‐α, 6‐β and 7‐β positions by 
various cytochrome (CYP) isoforms is the major BA detoxification pathway leading to 
the formation of the hydroxylated bile acids as hyocholic acid (HCA), muricholic acid 
(MCA) and ursodeoxycholic acid (UDCA) (Thakare et al. 2018). UDCA is by now the 
only drug approved by FDA for the treatment of primary sclerosing cholangitis and the 
medicamentous, non‐surgical dissolution of gallstones. Currently, UDCA is prepared 
industrially from cholic acid following a seven‐step chemical procedure with an overall 
yield of <30% (Munro et al. 2013). In goal, to reduce the number of steps to produce 
ursodeoxycholic acid, biotransformation has been successfully used (Bortolini et al. 
1997). Novel enzymatic bioconversions of free saturated bile acids are highly needed to 
obtain pharmaceutically significant compounds. Excellent tools to obtain hydroxylated 
bile acids are cytochrome P450 monooxygenases (P450s), which can catalyze the regio- 
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and stereospecific oxidation of non-activated hydrocarbons under mild conditions, which 
is a challenging task for chemical catalysts (Urlacher and Girhard 2012).  
One important family of bacterial P450s is the CYP107 family, as members of this 
family catalyze a variety of reactions in the secondary metabolism of bacteria, i.a, they 
are involved in the biosynthesis of many antibiotics (Parajuli et al.; Palaniappan et al. 
2003; Arakawa et al. 2006; Furuya et al. 2008). Moreover, enzymes of this family have 
the potential to be applied in the production of therapeutic drugs, vitamins and drug 
metabolites (Fujii et al. 2009; Milhim et al. 2016). Interestingly, a member of CYP107 
(CYP107D1) can catalyze the unspecific hydroxylation of testosterone at the positions 
6β, 7β, 12β and 15β by CYP107D1 (Figure 6.) (Agematu et al. 2006). 
 
Figure 6: Hydroxylation of Testosterone by CYP107D1(Agematu et al. 2006). 
 
What is more, not long ago, the crystal structure of CYP107D1 (pdb-code:4XE3, 5MNV- 
Figure 7) has been revealed. 
 
Figure 7: Crystallographic structure of clotrimazole bond OleP (Montemiglio et al. 2015).  
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The CYP107D1 (OleP) was discovered as the catalyzing enzyme responsible for 
the stereo- and regioselective epoxygenation of the aliphatic C8-C8a bond in the 
macrolide antibiotic oleandomycin (Montemiglio et al. 2015; Parisi et al. 2019). 
However, since CYP107D1 has been also shown to catalyze the hydroxylation of steroids 
compounds, and its crystal structure is known, it makes this P450 an even more 
interesting candidate to investigate. The aim of this study was to explore the potential of 
this enzyme to synthesize hydroxylated steroid compounds such as bile acids dedicated to 
pharmaceutical applications. 
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1.2.5 Hydroxylation of fatty acids using self-sufficient P450 
monooxygenase from Fusarium graminearum  
Fatty acids bearing a hydroxyl group display some special properties, such as higher 
viscosity and reactivity, compared to non-substituted fatty acids. Hence, hydroxy fatty 
acids have become  important building blocks for biodegradable polymer materials and 
for the cosmetic, chemical, pharmaceutical and food industries (Cao and Zhang 2013). 
However, most of these fatty acids are not commercially available because they are 
difficult to be synthesized via chemical routes. In contrast, a number of microorganisms 
are capable to produce hydroxy fatty acids from fatty acids or vegetable oils. Production 
of hydroxy fatty acids by microbial biotransformation offer the potential for 
transformation with high specificity and reduce the manufacturing cost compared to 
chemical synthesis routes (Cao and Zhang 2013; Kim and Oh 2013). Therefore, 
identification of novel enzymes to produce diverse hydroxy fatty acids is essential. 
Cytochrome P450 monooxygenases (P450s) take part in the stereospecific and 
regiospecific hydroxylation of non-activated hydroxycarbons, including fatty acids, under 
mild conditions (Van Den Brink et al. 1998; Honda Malca et al. 2012; Bernhardt and 
Urlacher 2014). Self-sufficient systems, where the P450 domain is naturally fused to its 
redox partners, are of particular interest since self-sufficient P450s are more efficient and 
stable than conventional P450s (Urlacher and Girhard 2012). However, until now, only 
two self-sufficient P450s are well described and can be implemented in industry. 
These P450s have been studied in the bacterium Bacillus megaterium BM3 
(CYP102A1) and the plant pathogenic fungus Fusarium oxysporum P450foxy 
(CYP505A1). Interestingly, both enzymes catalyze subterminal hydroxylations at the ω-1 
to ω-3 carbons of saturated and unsaturated fatty acids (Durairaj et al., 2015; Nakayama 
et al. 1996; Yadav et al. 2003; Lisowska et al. 2006)(Durairaj et al. 2015). Fungal genome 
sequencing projects have revealed the existence of more than 6000 fungal genes coding 
for putative P450s which are yet to be explored for the discovery of novel catalytic 
enzymes.  
Fusarium graminearum seems to be an excellent model organism because its 
genome has been sequenced, and genetic modification is relatively easy. The F. 
graminearum genome is expected to contain 119 putative CYP genes, and only nine F. 
graminearum CYPs have been functionally characterized (Shin et al. 2018). It is an 
excellent starting point for the discovery of novel self-sufficient P450, which show the 
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highest turnover numbers and coupling efficiency and allow CYPs to run with increased 
efficiency. Moreover, the most efficient way to use P450s for production of hydroxy fatty 
acids is to use the enzymes as whole-cell biocatalysts (Hammerer et al. 2018). 
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1.3 Transferases: Kinases 
Kinases are ubiquitous groups of enzymes, which catalyse the transfer of phosphate 
groups from high-energy, phosphate-donating molecules to specific substrates. This 
process is known as phosphorylation, where the substrate gains a phosphate group and the 
high-energy ATP molecule donates a phosphate group, produces a phosphorylated 
substrate and ADP. Kinase catalyzed phosphorylation of proteins, lipids, carbohydrates, 
nucleotides and can affect its activity, reactivity and its ability to bind other molecules. 
Therefore, kinases and their phosphorylated metabolites are critical in metabolism, cell 
signalling, protein regulation, cellular transport, secretory processes and many other 
cellular pathways, which makes them very important to human physiology (Cohen 2002; 
Fry et al. 2012; Attwood 2013; Baltussen et al. 2018; Roy et al. 2019). These 
phosphorylated metabolites can be directly isolated from natural resources. However, the 
yield of those high-value molecules through direct isolation is poor due to slow biomass 
accumulation and insufficient synthesis by the native host. Alternatively, phosphorylated 
metabolites can be obtained from chemical synthesis. However, selective phosphorylation 
in organic synthesis is challenging, involves numerous transformations for producing 
complex artificial compounds, which results in poor yield of phosphorylated 
metabolites(Wohlgemuth 2017).  
Therefore, making use of ubiquitous in nature and highly site-selective kinases for 
the synthesis of phosphorylated metabolites is a very promising route. Considering above, 
in this PhD thesis, two kinases were examined, and their ability for industrial production 
of phosphorylated metabolites. 
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1.3.1 Biocatalytic production of phosphorylated metabolites using 
kinases. 
Since chemical synthesis of phosphorylated metabolites is tedious, biocatalytic 
phosphorylation has a great advantage in improving molecular economy, safety, health, 
and environmental issues. Many phosphorylating enzymes such as kinases can be applied 
for mild biocatalytic phosphorylation reactions of metabolites without protecting groups 
and with high chemoselectivity, regioselectivity, and enantioselectivity (Wohlgemuth 
2017; Wohlgemuth et al. 2017). Kinases requires nucleoside triphosphates as cofactors. 
ATP is the most important biological phosphate donor and is a required cofactor for 
numerous enzymatic reactions in metabolism, specifically in the formation of P - O 
bonds. Direct cofactor addition is very uneconomic and leads to an accumulation of 
inhibitory cofactor by-products and challenging recovery of end products. Enzymatic 
systems for ATP regeneration have been developed to overcome these problems (Resnick 
and Zehnder 2000). Four enzymatic regeneration systems have been most often applied 
for ATP regeneration from ADP: a) acetylphosphate/acetate kinase, b) phosphoenol-
pyruvate (PEP)/ pyruvate kinase (PK), c) creatinphosphate/creatin kinase, d) 
polyphosphate/polyphosphate kinase. The PEP/PK system is considered as the most 
efficient ATP regeneration system. PEP is a stable phosphorylating agent and PK is 
commercially available on a large scale. Moreover, the PEP/PK have been successfully 
used in numerous preparative biocatalytic phosphorylations. (Andexer and Richter 2015). 
Therefore, the PEP/PK system for ATP regeneration was chosen in this thesis. 
Cloning and expression of kinases in E. coli, their characterization by determination 
of activity, and applying in selective phosphorylation while using the 
phosphoenolpyruvate/pyruvate kinase system for ATP regeneration, is of great interest 
for fast and robust method development for selective production of metabolites and 
metabolite-like structures (Figure 8). 
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Figure 8: Expression of kinases, characterization by determination of activity, biocatalysis using the 
phosphoenolpyruvate/pyruvate kinase system for ATP regeneration. 
  
Introduction 
31 
1.3.1.1 Biocatalytic synthesis of Nω-phospho-L-arginine by arginine 
kinase from Limulus polyphemus 
Nω-phospho-L-arginine is an instable form of energy-rich phosphoarginine, which 
makes chemical synthesis of this compound complicated. The instability of 
phosphoarginine results from the fact that in phosphoarginine the phosphate is attached to 
a nitrogen atom (N-phosphorylation) forming an acid-labile phosphoramidate bond, 
unlike in the case of O-phosphorylation, where the phosphate group is attached to a 
hydroxyl group, yielding a bond of lower acid lability. This is due to the protonation of 
the bridging nitrogen, which induces considerable lengthening and thereby weakening of 
the N-P bond. Hence, the high energy N-P bond in phosphoarginine is extremely acid 
labile, unstable in hot alkali, and sensitive to heat (Figure 9). 
 
Figure 9: Instable form of Nω-Phospho-L-arginine 
 
Several multistep chemical synthesis routes have been employed for the preparation of 
phosphoarginine. A few entirely chemical syntheses involving several reaction steps have been 
published, but each route has bottlenecks and challenges (Schoenenberger et al. 2017a). In 
contrast, arginine kineses are designed by nature to site-selective phosphorylation of arginine.  
Arginine kinase is found in a wide variety of invertebrates where it maintains ATP 
homeostasis during muscle contraction, ATP regeneration and energy transportation in 
cellular energy metabolism (Strong and Ellington 1993). Nω‐phospho‐L‐arginine has been 
found in biosynthetic pathways of parasites that are different from those pathways found 
in mammalian host tissues. Phosphoarginine plays a critical role as an energy reserve 
because it can be transferred to ATP when energy is needed. It is also a central reserve of 
high energy phosphate compounds in a wide variety of invertebrates and certain parasitic 
protozoa such as Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major, which 
cause some of the most debilitating diseases in humans including leishmaniasis, African 
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sleeping sickness, and Chagas disease (Li et al. 2006). This makes the metabolic pathway 
of phosphoarginine an attractive therapeutic target against parasitic diseases (Pereira 
2014). 
Arginine kinase, like the other phosphagen kinases, contain a signature peptide in the 
binding sites of substrates of five arginine residues interacting with ATP, two carboxylate 
amino acids, and one cysteine residue interacting with the guanidino acceptor group 
(Strong and Ellington 1995; Zhou et al. 1998a; Pereira 2014). Arginine kinase from 
Limulus polyphemus (Uni-prot P51541, KARG_LIMPO) is one of the best-characterized. 
Additionally, different crystal structures of this enzyme are available (Figure 10). 
 
Figure 10: Transition state structure of arginine kinase from Limulus polyphemus (Uniprot P51541, 
KARG_LIMPO)(Zhou et al. 1998b) 
 
Since arginine kinase from Limulus polyphemus is one of the best-characterized 
arginine kinase, it can be successfully applied for selective, biocatalytic phosphorylations 
in straightforward syntheses of phosphorylated metabolites like Nω-phospho-L-arginine 
using the phosphoenolpyruvate/pyruvate kinase system for ATP regeneration (Figure 11).  
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Figure 11: N-phosphorylation of L –arginine (Schoenenberger et al. 2017c). 
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1.3.1.2 Biocatalytic synthesis of shikimic-3-phosphate by shikimate 
kinase from E. coli 
Shikimic acid 3-phosphate is a central parasite, microbial and plant metabolite. It 
is found in a number of microbial pathogens such as Mycobacterium tuberculosis, 
Francisella novicida, Pseudomonas aeruginosa and Helicobacter pylori. Therefore, 
shikimic acid 3-phosphate is also crucial for developing shikimic acid kinase inhibitors to 
obtain new antimicrobials. Moreover, shikimic acid 3-phosphate is important as a 
substrate for 5-enolpyruvoyl-shikimate 3-phosphate synthase, which is of interest as a 
drug target in infectious diseases as well as in herbicides (Figure 12) (Oliveira et al. 2001; 
Dias et al. 2007; Schoenenberger et al. 2018). 
 
Figure 12: Biochemical mechanism for the herbicidal action of glyphosate through the inhibition of 5-
enolpyruvylshikimate 3-phosphate synthase (EPSPS) by the herbicide. 
 
The chemical synthesis of shikimate-3-phosphate is challenging due to the number 
of reaction steps, reaction times, hazardous/toxic chemicals. Since this key metabolite is 
still not available commercially, a selective one-step enzymatic phosphorylation of 
shikimic acid is necessary (Schoenenberger et al. 2018) (Shih and Wu 2000).  
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The shikimate pathway is essential in algae, higher plants, bacteria, fungi and 
parasites but is absent from mammals. Therefore, the shikimate pathway is an attractive 
target for the development of herbicides and antibiotic agents as well. Shikimate kinase 
(SK; EC 2.7.1.71), the fifth enzyme of this pathway, catalyzes the ATP dependent 
phosphorylation of shikimate to yield shikimate-3-phosphate. The shikimate kinase 
belongs to the NMP (nucleoside-phosphate kinase) structural kinase family, which 
consists of three domains: the core, having a highly conserved phosphate-binding loop (P-
loop); the nucleotide-binding domains, which upon binding shikimate and ATP (Figure 
13) undergo substantial conformational changes and require a divalent cation like 
magnesium or manganese for its activity; and the lid domain, which undergoes substantial 
conformational changes upon substrate binding (Dias et al. 2007; Schoenenberger et al. 
2018). 
 
Figure 13: Structure of shikimate kinase from Mycobacterium tuberculosis in complex with ADP, shikimate 
and Cl (Dias et al. 2007). 
 
Depending on the origin, the number of isoenzymes present varies. In Escherichia coli, 
the phosphorylation of shikimic acid is catalyzed by two isoenzymes, shikimate kinase I 
and II, which differ by their Km. The catalytically more active shikimate kinase II, 
corresponding to the aroL-encoded enzyme AroL, has a Km of about 200 μM for 
shikimate, whereas shikimate kinase I, corresponding to the aroK-encoded enzyme AroK, 
has a low affinity for shikimate with a Km of more than 20 mM (Schoenenberger et al. 
2018).  
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Therefore, application of shikimate kinase AroL from E. coli, as a route for 
selective biocatalytic phosphorylations in straightforward syntheses of shikimate-3-
phosphate using the phosphoenolpyruvate/pyruvate kinase system for ATP regeneration, 
is desired (Figure 14).  
 
Figure 14: Shikimate kinase-catalyzed phosphorylation of shikimic acid (Schoenenberger et al. 2018) 
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1.4 Lyases 
Lyases catalyze the cleavage or formation of C-C, C-N, C-O and other bonds to 
yield double bonds. Conversely, lyases can also catalyse the addition of groups to double 
bonds. The direction of the reaction will primarily depend on the equilibrium, constant for 
the reaction concerned. However, it may also be driven in a particular direction by the 
applied reaction conditions. Lyases differ from other enzymes in terms of two substrates 
involved in one direction of reaction and only one substrate involved in the reverse 
reaction. The elimination and addition reactions catalysed by lyases are described below 
(Figure 15). 
 
Figure 15: The elimination and addition reactions catalysed by lyases (van der Werf et al. 1994). 
 
In the EC number classification of enzymes, EC 4 represents lyases, which can be 
further classified into the following seven subclasses. Hydroxynitrile lyases, aldolases, 
ketolases, and a certain type of thiamine-diphosphate-dependent lyases play important 
roles in industrial biotransformations. Moreover, halohydrin dehalogenases are useful 
biocatalysts for the production of enantiopure epoxides as well as they exhibit epoxide 
ring‐opening activity with a range of small anionic nucleophiles such as azide, cyanide, 
nitrite, cyanate or thiocyanate, which is even more attractive as it enables the regio‐ and 
stereoselective formation of novel C−N, C−C, C−O and C−S bonds (Figure 16) 
(Calderini et al. 2019) 
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Figure 16: Classification of lyases and representative examples of lyase catalyzed reactions 
Lyases in EC 4.1 cleave carbon-carbon bonds and include decarboxylases (EC 4.1.1 pyruvate 
decarboxylase) and aldolases (EC 4.1.2.4 2-deoxy-D-ribose 5-phosphate aldolase) (Jennewein et al. 2006). 
EC 4.2 contains a group of lyases that break carbon-oxygen bonds, such as dehydratases (carnitine 
dehydratase EC 4.2.1.89, nitrile hydratase EC 4.2.1.84) (Jung et al. 1989; Cánovas et al. 2005; Martinez et 
al. 2014; Lan et al. 2017). Lyases cleaving carbon-nitrogen bonds are sorted into EC 4.3 (phenylalanine 
ammonia lyase EC 4.3.1.24) (Bartsch and Bornscheuer 2010). Lyases in EC 4.4 cleaves carbon–sulfur 
bonds. Lyases cleaving carbon-halide bonds belong to EC 4.5 (halohydrin dehalogenases (EC 4.5.1.-)). 
(Calderini et al. 2019). EC 4.6 comprises lyases fracturing phosphorus-oxygen bonds, like adenylyl cyclase 
and guanylyl cyclase. EC 4.99 is a group of other lyases (Mahdi and Kelly 2008). 
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1.4.1 Biocatalytic synthesis of L-argininosuccinate using 
argininosuccinate lyase from Saccharomyces cerevisiae 
Arginine metabolism has been recognized as a process of increasingly high 
importance for the study of tumour development and progression, since many tumour 
cells have lost the ability to produce L-arginine de novo. As an expression of the urea 
cycle, argininosuccinate synthetase enzyme decrease can be observed in melanoma, 
mesothelioma and cancers of the liver, kidney, pancreas, prostate and ovary. As a result, 
argininosuccinate formation is reduced, and aspartate is accumulated, enhancing the 
proliferation of cancer cells. Nitric oxide (NO), generated through L-arginine metabolism, 
has been linked to cardio-vascular diseases.
 
L-Arginine and its metabolic pathways also 
affect the immune system by its impact on human T cells and T cell receptors. 
Additionally, it has a key role in the inflammatory function of macrophages, where the 
nitric oxide synthesis pathway is associated with the inflammatory M1 phenotype, while 
the arginase pathway is associated with the tolerant M2 cell phenotype (Schoenenberger 
et al. 2017b).  
In the urea cycle, L-argininosuccinate is the product of the ATP dependent and 
rate-limiting reaction of citrulline and aspartate, catalysed by the argininosuccinate 
synthase enzyme (ASS). Subsequently, L-argininosuccinate is cleaved into fumarate and 
arginine by the argininosuccinate lyase enzyme (ASL) (Figure 17).  
 
Figure 17: ASL is indicated in the red box as the fourth enzyme of the urea cycle (Schoenenberger et al. 
2017b). 
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The highly conserved ASL enzyme has been studied in a wide range of organisms 
including rat, human, Escherichia, algae, saccharomyces and amphibian. It has been 
found to be active as a tetramer of identical monomers (Figure 18), where each subunit 
has a single polypeptide between 49–52 kDa (Yu and Howell 2000). 
 
Figure 18: Structure of ASL from Saccharomyces cerevisiae (P04076 (ARLY_strain ATCC 204508 / 
S288c) (Baker's yeast)) 
 
Interestingly, ASL can also catalyse the reverse reaction to form L-argininosuccinate from 
arginine and fumarate in an ATP-independent manner as shown by Ratner et al., when 
fumarate and arginine have been used in excess to shift the equilibrium of the reaction 
(Figure 19) (Murakami-Murofushi and Ratner 1979). 
 
Figure 19: Argininosuccinate lyase-catalyzed reaction between arginine and fumarate argininosuccinate as 
part of the urea cycle running in reverse. 
 
Since ASL can also catalyse the reverse reaction to form L-argininosuccinate from L-
arginine and fumarate, a recombinant overexpression strategy for argininosuccinate lyase 
(ASL) employing the ARG4 gene from Saccharomyces cerevisiae (Uniprot P04076, 
ARLY_YEAST) was used in this thesis to develop a simple biocatalytic procedure for the 
synthesis of L-argininosuccinate. 
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2 Aim of this thesis 
The pharmaceutical industry requires novel synthetic routes that are environmentally 
friendly. Biocatalysis that uses either isolated enzymes or whole-cell catalysts is becoming 
essential. Moreover, enzymes are excellent tools for chemical biology research and the 
analysis of complex, biological mechanisms. Therefore, the aim of this thesis was the 
enzymatic synthesis of bioactive molecules such as hydroxy fatty acids, phosphorylated 
compounds and bile acids. 
2.1 Biosynthesis of bile acids using P450 monooxygenase 
Bile acids can take over various roles in the human body, e.g. they can act as 
emulsifiers of lipid aggregates, transporters of lipids, function as hormones in cholesterol 
biosynthesis or promote liver regeneration. Since P450 monooxygenases are involved in the 
cholesterol catabolic pathway, they are the crucial biocatalysts for the formation of different 
bile acids, vitamin D derivatives and steroid hormones. Nevertheless, knowledge of bacterial 
P450s, which can convert bile acids selectively, is scarce. Therefore, the aim of this thesis was 
to develop a straightforward biocatalytic hydroxylation of certain 5β-cholanoic acid 
derivatives with high regio- and stereoselectivity employing the P450 monooxygenase OleP 
from Streptomyces antibioticus together with the heterologous redox partner system Pdx/PdR. 
2.2 Biosynthesis of hydroxy fatty acids using P450 monooxygenase  
Hydroxy fatty acids are essential chemicals for versatile applications, but their 
commercial availability is limited because they are difficult to be synthesized via chemical 
routes. Cytochrome P450 monooxygenases (P450s) are interesting catalysts due to their 
ability to selectively hydroxylate non-activated hydrocarbons. However, only a few P450-
catalyzed processes have been industrially implemented due to the difficulty of developing 
economically feasible processes with such enzymes. Self-sufficient monooxygenases, in 
which the heme domain and the flavin reductase domain are fused, offer high potential to 
overcome this challenge. The fungal kingdom is a high source of still unexplored P450s, 
including many self-sufficient ones. The plant pathogenic fungi Fusarium graminarium 
possesses large numbers of P450s, which are involved in diverse biological processes, 
including production of primary and secondary metabolites and denitrification. Until now, 
only few fungal P450s have been functionally characterized. Therefore, investigation of 
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fungal P450s may offer opportunities to exploit their catalytic functions to produce 
hydroxylated fatty acids. 
2.3 Biosynthesis of Nω-phospho-L-arginine by arginine kinase 
The lack of availability of Nω-phospho-L-arginine, which is present in invertebrates to 
regulate energy requirements when it is highly needed, was due to a tedious chemical 
procedure, during which the Nω-phospho-L-arginine, was prepared in over five reaction steps 
in a low yield. The medically important protozoa, which causes some of the most debilitating 
diseases in humans, including leishmaniasis, African sleeping sickness, and Chagas disease, 
can serve as an example of such invertebrate. Taking the above into consideration, the 
objective of this study was to develop a straightforward biocatalytic procedure for the 
phosphorylation of L-arginine, to Nω-phospho-L-arginine, on the gram scale, employing site- 
and enantioselective arginine kinase. 
2.4 Biosynthesis of shikimic-3-phosphate by Shikimate kinase 
Since shikimic acid-3-phosphate is of high interest as an enzyme-substrate for 5-
enolpyruvoyl-shikimate 3-phosphate synthase, a drug target in infectious diseases and a prime 
enzyme target for the herbicide glyphosate, industrial environmentally friendly production of 
this molecule isof high interest. Biocatalysis has the potential to deliver such ‘greener’ 
chemical syntheses. For this reason, Shikimate kinase (AroL) from E. coli was chosen as a 
tool for the biosynthesis of a central metabolite of the shikimate pathway, Shikimic acid-3-
phosphate, at multi-gram scale. 
2.5 Biosynthesis of L-argininosuccinate by argininosuccinate lyase  
The primary natural amino acid L-argininosuccinate containing two chiral centres 
occurs in the L-alanine, L-arginine, L-aspartate, L-glutamate and L-proline metabolic pathways 
and plays a role in the biosynthesis of secondary metabolites and other amino acids. The aim 
of this work was to develop a simple and straightforward biocatalytic procedure for the 
synthesis of N-(([(4S)-4-Amino-4-carboxybutyl]amino)iminomethyl)-L-aspartic acid lithium 
salt (L-argininosuccinate). It was proposed to achieve this goal by running part of the urea 
cycle in reverse. Argininosuccinate lyase (ASL) from Saccharomyces cerevisiae was chosen 
Aim of this thesis  
 
43 
as the catalyst for this addition reaction. Using this argininosuccinate lyase, a novel, green 
synthesis route for this important metabolite can be developed. 
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3 Results and discussion 
3.1 Cytochrome P450 monooxygenase CYP107D1 OleP from Streptomyces 
antibiotics 
Bacterial P450 systems usually require the presence of FDR and FDX in order to 
couple electron flow from NAD(P)H to the terminal P450 component. Most of the bacterial 
P450s are class I, P450s, receiving electrons from a two-component reductase system, FDX 
and NADH FDR, such as in P450cam. Several redox systems (putidaredoxin reductase (PdR) 
– putidaredoxin (Pdx) from Pseudomonas putida, ferredoxin reductase (FdR) – ferredoxin 
(Fdx) from Escherichia coli, adrenodoxin reductase (AdR) – adrenodoxin (Adx) from bovine) 
have been used in different ratios to reconstitute the activity of various P450s. The most 
commonly employed redox system is the P450cam system from Pseudomonas putida. The 
P450cam monooxygenase system consists of three separate proteins. The PdR (putidaredoxin 
reductase- CamA) is a FAD-containing, strictly NADH-dependent protein, while PdX 
(putidaredoxin-CamB) is an iron sulfur protein that belongs to the group of [2Fe–2S] FDX 
and plays the role of an electron shuttle transferring the two electrons, one at a time, from 
CamA to P450cam (Sevrioukova and Poulos 2011; Urlacher and Girhard 2011). 
Since the most widely used redox system is the P450cam and no physiological redox 
partners of CYP107D1 have been identified yet, the biotransformation system was designed 
to co-express CYP107D1 cytochrome P450, from Streptomyces antibiotics, along with PdR 
(putidaredoxin reductase) and PdX (putidaredoxin) from Pseudomonas putida. This was 
carried out using two plasmids with different selection markers and compatible origins of 
replication. The PdX/PdR was cloned into the pACYC vector and CYP107D1 was cloned into 
pET28a (+) vector. 
The aim of this study was to investigate a whole-cell biocatalyst based on Escherichia 
coli expressing CYP107D1 together with corresponding redox partners to develop a 
straightforward biocatalytic procedure for the selective hydroxylation of bile acids. 
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3.1.1 Recombinant coexpression of CYP107D1 together with redox 
partners and purification of P450_CYP107D1. 
E. coli C43(DE3) was chosen as host strain for the efficient expression of all three 
proteins (CYP107D1, PdX and PdR). E. coli naturally does not contain any endogenous heme 
proteins like P450 enzymes, the presence of which could result in undesired background 
activity (Bracco et al. 2013b). Since E. coli lacks P450s, the addition of δ-aminolevulinic 
acid, a precursor for the heme synthesis, is necessary (Lundemo and Woodley 2015). The 
expression factors such as temperature, length of growth and media supplementation affect 
the yield of protein expression. In general, E. coli transformed with a P450 plasmid are grown 
in supplemented Terrific Broth media for an extended period at low temperatures with 
aeration. Moreover, lower expression temperature has been reported to yield stable expression 
of proteins without aggregation. However, the low temperature can also lead to low 
expression (Zelasko et al. 2013). Therefore, different strategies were applied in order to 
increase the amount and activity of soluble P450 CYP107D1 and its redox partners’ genes 
expressed in E. coli. The influence of different media (TB, Power Broth, LB), temperature, 
aeration during expression (baffled and non-baffled shake flasks), as well as duration of 
expression and the supplementation with a heme precursor (δ-aminolevulinic acid, FeSO4, 
hemin) was tested. It is recommended by the manufacturer of the pET system to lower the 
temperature during expression to achieve more soluble, active enzyme. However, an 
expression temperature of 30°C turned out to be more efficient than lower temperature of 
20°C. Expression of CYP107D1, and PdR/PdX was confirmed by SDS-PAGE (Figure 20 A). 
The size of the expressed CYP107D1 was approximately 46 kDa, whilet the redox partner 
proteins were 45 kDa (PdR) and 11 kDa (PdX) as determined by SDS-PAGE analysis (Figure 
20A). Since the recombinant OleP carried an N-terminal His-tag, it could successfully be 
purified by IMAC (Figure 20 B).  
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Figure 20: (A) Recombinant expression of P450 CYP107D1 and PdX/PdR. (B) SDS-PAGE analysis showing 
His-tag purification of the recombinant CYP107D1. 
 
(A) Lane 1: marker, lane 2: soluble fraction of the cell crude extract from E. coli (PdX/PdR), lanes 3-5: soluble 
fraction of the cell crude extract from E. coli (CYP107D1+PdX/PdR) MW of CYP107D1: ~ 46 kDa, PdX: ~11 
kDa, PdR: ~45 kDa. (B) SDS-PAGE analysis showing His-tag purification of the recombinant CYP107D1. (B) 
Lane 1: marker, lanes 2-7: elution of purified CYP107D1, MW of CYP107D1: ~ 45 kDa. 
Moreover, highest biomass production was achieved in TB medium respectively, in 
comparison to LB and Power Broth. Beside higher biomass production, TB medium also 
sustained the higher expression of CYP107D1, measured as volumetric productivity (data not 
shown). 
Since it is well recognized that conventional electrophoresis conditions result in the 
nearly complete dissociation of heme from P450 holoprotein, to provide an independent 
evaluation of the nature of the heme-P450 interaction in CYP107D1, SDS-PAGE analysis 
with TMBZ/hydrogen peroxide staining was conducted specifically for detection of the heme 
group (Figure 21). Intense staining in the 46 kDa region is evident for the CYP107D1 
preparation. 
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Figure 21: SDS-PAGE developed with TMBZ/hydrogen peroxide stain specific for heme. 
Lanes: 1, molecular weight markers; 2, Cytochrome C; 4, CYP107D1 
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3.1.2 Spectral features of the CYP107D1 enzyme and NADPH–P450 
reductase activity 
Reduced heme iron of the CYP forms an adduct with CO and the resulting CYP-CO 
complex gives a characteristic peak near 450 nm. This technique has been extensively used 
for the quantification of active CYPs from the absorbance difference of A450–490 using the 
molar extinction coefficient of 91 mM
-1
cm
-1
 (Lamb and Waterman). To determine the 
concentration of active CYP107D1, CO-difference spectra were measured. Correct insertion 
of the heme prosthetic group is indicated in these spectra by a typical absorption maximum at 
450 nm. In contrast, inactive P450 enzymes show a peak at 420 nm (Luthra et al. 2011).  
Moreover, baffles are often used in shake flasks to increase oxygen transfer into the 
flask (Gupta and Rao 2003). Therefore, the impact of baffled flasks on the biomass 
measurement and P450 concentration was investigated. The effect of baffles and different 
sterile closures in a shake flask have been tested on the cell growth during E. coli 
fermentation (50 mL scale). An experiment performed with three non-baffled flasks covered 
with different plugs (cotton, sponge, and milk filter) and a baffled flask covered with filter 
showed that the difference in the oxygen transfer rate in a shake flask under varying 
conditions led to different oxygen level during fermentation. If the dissolved oxygen 
concentration falls below the critical level, then the cells may be metabolically disturbed. The 
impact of oxygen transfer was not limited only to the biomass growth rate, but it also affected 
the expression level of P450. As shown in Figure 22, the P450 concentration of P450 in 
baffled flask (0.129 nmol mL
-1
) was 40% higher than in non-baffled flask (0.086 nmol mL
-1
). 
 
Figure 22: Examination of the influence of aeration with baffled and non-baffled shake flask on the CYP107D1 
concentration. Concentration of the recombinant P450 CYP 107D1 expressed in E. coli in cultures in baffled 
(black column) and non-baffled (gray column) flasks. The reduced CO-difference spectral analysis carried out, 
here, for the purified CYP107D1. 
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Hence, for larger scale (400 mL) expression baffled shake flask was chosen. The reduced CO-
difference spectral analysis carried out, here, for the purified CYP107D1 resulted in a 
maximum absorption at 450 nm. This confirms the active nature of the purified CYP107D1 
(Figure 23). Based on the CO-difference spectra, the concentration of purified CYP107D1 
was estimated to be 16.92 nmol mL
-1
.  
 
Figure 23.: CO binding analysis of purified CYP107D1 expressed in E. coli.  
 
Earlier, Rodriguez et al. has already described the expression of OleP in E. coli as a 
fusion protein to a maltose-binding protein but in their work the enzyme was inactive 
(Rodriguez et al. 1995). In contrast, obtained results indicate that the recombinant OleP with 
N-terminal His-tag was overexpressed in E. coli as a soluble and what is more important an 
active cytochrome P450. 
The catalytic activity of P450s requires one or more redox partners to transfer two 
electrons from NAD(P)H to the heme iron. The efficiency of electron transfer directly affects 
the overall rate of P450-catalyzed reactions. Therefore, determining the activity of the 
PdX/PdR redox system was essential. The cytochrome P450 reductase is capable of 
transferring electrons not just to P450, but to artificial acceptors, such as cytochrome c (cyt c) 
and 2,6-dichlorophenolindophenol (DCIP), as well. These molecules serve as model 
substrates for the reductase to assess how alterations in structure or reaction conditions affect 
enzyme catalysis. Spectrophotometric assays were used reduction of cytochrome c, and 
DCPIP and NADPH utilization (Gray et al. 2010). The activity of PdX and PdR from 
Pseudomonas putida was investigated by adding NADPH and DCPIP. Here, a fast NADPH 
depletion was observed along with the conversion of dark blue DCPIP to its colorless reduced 
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form. Based on the DCPIP assay, the obtained specific activity of the electron transfer 
components was in the range of 1.0 to 1.1 U mL
-1
. Therefore, PdX and PdR from 
Pseudomonas putida can be applied as surrogate electron transfer partners required for 
CYP107D1 activity.  
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3.1.3 OleP -Substrate screening 
Information on substrate selectivity is key to the understanding of the P450’s function. 
In addition, once the CYP107D1 crystal structure is known, a comprehensive understanding 
of changes in substrate selectivity enables the design and creation of a CYP107D1 mutant 
with the desired selectivity. Since CYP107D1 is able to hydroxylate testosterone, this P450 is 
an excellent candidate as catalysts for the synthesis of high-value hydroxylated steroid 
molecules, such as hydroxylated bile acids.  
In this research an integrated P450 substrate screening system to select “sample” 
substrates for the P450 of interest was developed. Because of the limitations of P450s as 
biocatalysts on industrial scale such as cofactor dependency, low stability and catalytic 
activities in isolated form, it is often favored to use them as whole cells rather than isolated 
enzymes. Biotransformations using whole cells show advantages since this is the most 
efficient solution for cofactor regeneration. The cofactor recycling step is carried out within 
the intact cell, driven by the reduction equivalents introduced via the external carbon and 
energy source (glucose). What is more, whole cells allow biotransformation on larger scale, 
especially when the microorganisms applied as expression host can be cultivated in high cell 
density (Rasor and Voss 2001; Ghisalba, O., Meyer, H. P., & Wohlgemuth 2010; Hernández-
Martín et al. 2014; Lundemo et al. 2016). In order to set up optimal biotransformation 
conditions for the resting cells of E. coli C43(DE3) (pET28a(+)CYP107D1) 
(pACYCcamAB), and to enable NADH regeneration within the E. coli metabolism, the buffer 
was supplemented with glucose and glycerol (Glazyrina et al. 2010). A library of 22 steroid 
compounds and 4 fatty acids were screened as a potential substrate for CYP107D1 using the 
whole-cell biotransformation (steroids and fatty acids tested in this study as substrates for 
CYP107D1 can be found in the Appendix: Table A 1). For biotransformation, the substrate 
was added to a final concentration of 2 mg mL
-1
 from a 100 mg mL
-1
 stock solution in 
DMSO. Reactions were incubated at 28°C with shaking at 160rpm. Samples (1 mL) were 
taken over a period of 24 h extracted twice with 1 mL ethyl acetate and centrifuged (13300 g, 
5 min) to remove cells. The supernatants were used for products quantification. The 
biotransformation reactions were initially followed by thin layer chromatography (Figure 24). 
Three of the tested substrates has shown conversion: testoserone (Figure 24a), LCA (Figure 
24b), and DCA (Figure 24c). TLC analysis showed that OleP accepted testosterone as a 
substrate resulting in several reaction products, in agreement with the preliminary findings of 
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Agematu et al.(Agematu et al. 2006). The identity of the diverse hydroxylated testosterone 
derivatives hasn’t been confirmed, since testosterone was not in the focus of this study. 
 
Figure 24.:a) Conversion of testosterone; b) conversion of LCA; c) conversion of DCA detected on TLC; LCA-
P- product of conversion of LCA by OleP with PdX/PdR; T-P1-4 - product of conversion of testosterone by 
OleP with PdX/PdR; DCA-P - product of conversion of DCA by OleP with PdX/PdR. 
 
In addition, CYP107D1 also accepted LCA and DCA bile acids as substrates, in both 
cases giving only one product selectively. To the best of current knowledge, CYP107D1 is the 
first reported P450 that can catalyze the hydroxylation of LCA and DCA with high selectivity. 
Moreover, such selective reactions performed by CYPs are extremely hard to achieve via 
conventional chemical routes. Therefore, this promising reaction was further studied. 
Both isolated enzymes and whole cells have been used as catalysts. However, the 
application of the whole cells for bile acids biotransformation resulted in higher conversions 
than cell-free extract (based on TLC). Enzymes in cells are protected from the external 
environment, thus, they are generally more stable in the long-term than free enzymes. 
Moreover, in vivo catalysis mostly solves the problem of cofactor regeneration. Furthermore, 
the best conversion of LCA and DCA was obtained with enzymes expressed at 30°C. In the 
control reactions with E. coli C43(DE3) (PdR/PdX) not expressing CYP107D1, no product 
formation was observed (Figure 25). 
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Figure 25: TLC results on biotransformation of LCA (25a) and DCA (25b) OleP and PdR/PdX as redox partner 
From left to right: 1 spot: LCA-control; 2 spot: LCA- PdR/PdX control; 3 spot: LCA CYP107D1+PdR/PdX 
expressed at 30°C (expression 1); 4 spot LCA CYP107D1+PdR/PdX expressed at 30°C (expression 2); 5 spot: 
LCA CYP107D1+PdR/PdX expressed at 20°C (expression 1); 6 spot: LCA CYP107D1+PdR/PdX expressed at 
20°C (expression 2); 7 spot: LCA CYP107D1+PdR/PdX expressed at 20°C (expression 3); 8 spot: DCA -
control; 9 spot: DCA CYP107D1+PdR/PdX expressed at 30ºC (t0); 10 spot: DCA CYP107D1+PdR/PdX 
expressed at 30°C (t1(12h));11 spot CYP107D1+PdR/PdX expressed at 30°C (t1(24h)).  
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3.1.4 Identification of products  
The biotransformation products were isolated by column chromatography. Their 
structure was verified by 2D-NMR experiments (2D NMR analysis can be found in the 
Appendix: Figure A 1 and Figure A 3) and mass spectrometry (MS) (MS analysis can be 
found in the Appendix: Figure A 2 and Figure A 4). The structure elucidation revealed that in 
both cases the hydroxylation occurred stereoselectively, resulting in a new hydroxyl group in 
the 6β position. The product obtained from DCA was 3α,6β,12α-trihydroxy-5β-cholan-24-oic 
acid. This hydroxylated derivative of DCA has been synthesized before by a tedious time-
consuming chemical method (Iida et al. 1986). The product obtained from LCA was 
murideoxycholic acid, which is a known metabolite in humans and house mice (Figure 26).  
 
 
Figure 26: OleP (CYP107D1) catalyses the conversion of LCA or DCA into the corresponding 6-hydroxylated 
products. 
 
DCA is a component of human bile acid, which plays an important role in emulsifying 
and digesting fat in the intestine (Virtanen and Kolehmainen 2004). Moreover, DCA and its 
sodium salt are globally approved drug products for decades; they have diverse applications in 
the pharma and beauty industry such as treatment of lipomas as an alternative to surgical 
excision, or the disruption of Influenza viruses during vaccine production (Rotunda et al. 
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2004, 2005; Arnold and Linke 2008; Ascher et al. 2016). Therefore, since DCA is widely 
used in medicine, more knowledge about its possible metabolites becomes essential.  
In this study DCA was used in whole-cell biotransformation at 200 mL scale with 200 
mg DCA. Starting from the DCA material (2 mg mL
-1
 5.51 mM or 5.51 μM mL-1)), 0.7 mg 
mL
-1
 (1.7 mM) 6β_DCA was produced within 24 h, resulting in a yield of 35 %. This led to 
1.7 mmol L
-1
 of 6β_DCA in the culture and a space-time yield of 0.071 mM h-1. Calculations 
were based on the dry cell weight of E. coli and the cell density of the culture (OD600 = 18): 
one liter of culture yields 7.02g of dry cells, which consequently leads to 0.26 mmol/gCDW.  
The structural difference between LCA and DCA is the additional 12α-hydroxyl group 
in the DCA which changes the hydrophilic-hydrophobic balance of the bile acid leading to 
overall higher hydrophilicity of the compound (Monte et al. 2009). Based on the results of 
TLC, which is a qualitative and straightforward method, HPLC analysis was performed. For 
further characterization, the time course of product formation during whole-cell conversions 
of LCA showed that the product distribution changed over time. Samples were taken every 2 
h over 24 h with a break after 12 h (Figure 27). 
 
Figure 27: Whole-cell biotransformation of 5.31 mM LCA using E.coli C43 (DE3) co-expressing OleP and 
PdR/PdX. The percentage and amount (in mg) of LCA converted to MDCA at each time point is plotted as mean 
with standard deviation (n=3) (Grobe et al. 2020). 
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As indicated in Figure 27, MCA was found to be the main product in the first 8-12 
hours of the reaction, and it is dependent on the activity of CYP107D1. The error bar 
indicates that only a small amount of MCA is produced between 12 and 24 hours of the 
reaction. Based on the time course and a standard curve for MCA, the yield can be 
determined. Starting from the LCA material (2 mg mL
-1
 (5.31 mM or 5.31 μM mL-1)), 0.39 
mg·mL-1 (0.99 mM) MCA was produced within 24h, resulting in a yield of 19.5 % MCA. 
This led to 0.998 mmol L
-1
 of MCA in the culture and a space-time yield of 0.042 mM·h-1. 
Calculations were based on the dry cell weight of E. coli and the cell density of the culture 
(OD600 = 18): one liter of culture yields 7.02 g of dry cells, which consequently leads to 0.14 
mmol/gCDW.  
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3.1.5 Discussion 
Applying a heterologous three-component system (CYP107D1+PdR/PdX) in the 
bioconversion of LCA, we have shown that CYP107D1 is not only involved in oleandomycin 
biosynthesis as described by Montemiglio et al., but also exhibits excellent regio- and 
stereoselectivity for LCA and DCA, producing 6β-hydroxylated bile acids exclusively 
(Montemiglio et al. 2015; Parisi et al. 2019). Agematu et al. expressed a CYP107D1 with 
PdR/PdX as a redox partner in E. coli and reported  OleP hydroxylated testosterone at the 6β-, 
7β-,12β and 15β- positions, indicating that OleP was a multifunctional P450 (Agematu et al. 
2006). The different selectivity of OleP, observed in this study, can be explained by the 
differences in the steroidal structure. While testosterone contains a double bond between C4 
and C5 and the A/B ring fusion has a trans conformation, the A/B ring in the bile acids is cis, 
creating a significant spatial difference between the molecules (Li and Chiang 2014). 
Hydroxylation of LCA in 6β-position was also described in the literature for eukaryotic P450 
monooxygenase from Golden hamster CYP3A10, which has only 20% similarity to OleP 
(Teixeiras and Gilg 1991; Chang et al. 1993). In humans, by contrast, P450 CYP3A4 
hydroxylate steroid hormones on position 6β can also metabolize lithocholic acid, but in this 
case the bile acid is hydroxylated at the 6α position. Since DCA is widely used in medicine 
and the possibility of producing its metabolites has become important. The synthesis of 6β-
hydroxylated DCA starting from DCA was previously described in 11 steps with an overall 
yield below 20% which is time-consuming and a complicated procedure compared to one-step 
biotransformation using CYP107D1 (Iida et al. 1986). OleP is the first bacterial P450, which 
selectively hydroxylates bile acids on the 6β position and thus provides the opportunity to use 
it as an alternative drug target for metabolic disorders, cancer, and also as antimicrobial agent. 
In summary, CYP107D1 from Streptomyces antibioticus represents a promising new 
biocatalyst for hydroxylation reactions. The enzyme can be easily expressed with the redox 
partners PdX/PdR in E. coli. OleP has been found to hydroxylate certain bile acids in a regio- 
and stereoselective manner. The multifunctionality of OleP opens up new horizons for the 
commercial production of physiologically active steroids, which are difficult to obtain from 
alternative steroid raw materials.  
Moreover, since the CYP107D1 crystal structure has been known, it is a good starting 
point for protein engineering to modify the selectivity of the enzyme. The organic synthesis of 
the API bile acid UDCA is a long process. Nowadays organic synthesis of UDCA is 
complicated and risky due to the nature and toxicity of the reagents used, the costs of disposal 
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of large amounts of sodium hydroxide, chromium salts and organic solvents, and the 
purification processes necessary to eliminate byproducts formed at each step of reaction 
involved (Tonin and Arends 2018). Therefore, research nowadays is geared towards more 
economical synthesis methods that are waste-free and safe to operate. An approach that bears 
great promise is the biotransformation with non-pathogenic, easy-to-manage microorganisms 
as E. coli. The one-pot or one-flow reaction, involving highly selective enzymatic steps would 
be preferred. Therefore, designing a CYP107D1 mutant with 7β-hydroxylation activity 
towards LCA can lead to the discovery of a new commercial path to the production of the 
UDCA. 
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3.2 P450 monooxygenases from Fusarium graminarium 
To explore the diversity of fungal P450 systems, a search through the Fungal 
Cytochrome P450 Database was performed (Park et al. 2008). The genome of F. graminarium 
is predicted to contain 119 putative CYP genes and only nine CYPs have been functionally 
characterized three of those are paralogs of CYP51, which encodes an ergosterol biosynthetic 
enzyme (Shin et al. 2018). Out of 119 P450s from F. graminarium, only three have been 
recognized as self-sufficient: (P450_FG07 (UniProt-I1RTT0_GIBZE), P450_FG060 (Uni- 
Prot- A0A098D0P1_GIBZE), P450_FG067 (UniProt-I1RE90_GIBZE). Self-sufficient P450s 
from F. graminarium are grouped into two classes according to their topology (Figure 4), 
which differ in the arrangement of the P450 redox partners and associated fusion proteins. 
The P450_FG07 (UniProt-I1RTT0_GIBZE) and P450_FG067 (UniProt-I1RE90_GIBZE) are 
in the class VIII topology, the heme-monooxygenase domain is fused to a FAD- and FMN-
containing NADPH-cytochrome P450 reductase (Fig. 4-I). In contrast, the heme-
monooxygenase domain of P450_FG060 (UniProt-A0A098D0P1 _GIBZE) is fused to a FMN 
and iron-sulfur cluster-containing reductase (Class VII) (Fig. 4-H). Interestingly, BLAST 
analysis showed that the amino acid sequence of P450_FG067 from F. graminarium showed 
shared 86% identity with P450foxy from F. oxysporum. The P450foxy (CYP505A1) is 
already characterized as a self-sufficient ω-1, ω-2, ω-3 fatty acid hydroxylase (Nakayama et 
al. 1996; Kitazume et al. 2002, 2008). The prediction of function only from protein structure 
similarity is however challenging as combined information about sequence, structure, and 
function is often still missing. This makes an activity screening inevitable. Therefore, 
P450_FG067 was chosen for further investigation as novel self-sufficient P450 for fatty acid 
hydroxylation. Moreover, use of microorganisms, such as E. coli or P. pastoris, as a whole-
cell biocatalyst protects the enzymes from destabilization and degradation and appears to be a 
useful alternative to the enzymatic approach for the bioconversion of fatty acids (Kelly et al.; 
Bernhardt 2006; Hernández-Martín et al. 2014).For expression of the eukaryotic P450-FG067 
(UniProt: I1RE90_GIBZE), the two host systems P. pastoris and E. coli were compared. Both 
hosts have been widely used the for expression of P450s. Synthetic gene for P. pastoris was 
codon-optimised and equipped with a C-terminal 6x-His-tag. For an expression in E. coli, an 
expression plasmid harbouring P450_FG0067 was constructed. The gene was amplified and 
subcloned to the pET24a vector. Plasmid pET24a was considered to be the most suitable over 
expression vector, providing kanamycin resistance, the T7 promoter and encodes a C-terminal 
hexa-histidine tag for the affinity purification. The strategy of subcloning of P450_FG0067 
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into pET24 vector can be found in the Appendix: Figure A 8. A DNA insert encoding the 
P450_FG0067, using the pUC_P450_FG0067 plasmid as a template, was prepared by PCR 
using the primers containing an HindIII and BamHI restriction site. Specific PCR products of 
the approximate expected size (3330 bp) were obtained (PCR amplification of P450-FG067 can 
be found in the Appendix: Figure A 9). The resulting PCR product containing P450_FG0067 
gene was placed under the control of a tac promoter by digesting the amplicon with HindIII 
and BamHI, and ligating into a HindIII and BamHI-digested pET24a, yielding plasmids 
P450_FG067_pET24a (PCR control to monitor the integrity of P450-FG067 amplicons in PET24a 
vector can be found in the Appendix: Figure A 10). 
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3.2.1 Expression and activity determination in E. coli 
While many proteins can be successfully expressed to very high levels in E. coli 
BL21(DE3), in some cases, significant over-production cannot be achieved because of the 
toxicity of the target protein, which may even cause bacterial cell death. The P450s are heme 
proteins and over-expression of heme binding proteins in E. coli often results in sub-optimal 
heme incorporation into the recombinant proteins. Moreover, the target protein P450-FG067 
is an eukaryotic protein with high molecular weight (120 kDa). It has been reported that 
proteins with molecular weights above 60 kDa are difficult to express. Since E. coli 
C43(DE3) strain is effective in overexpressing toxic and membrane proteins from all classes 
of organisms, including viruses, eubacteria, archaea, yeasts, plants, insects, and mammals, 
therefore, this strain was chosen for expression of eukaryotic P450-FG067 (Dumon-
Seignovert et al. 2004). Supplementing the growth media with δ-amino levulinic acid (δ–
ALA), a precursor of the heme biosynthesis pathway, increases levels of heme biosynthesis 
and thereby heme incorporation into the target protein (Delcarte et al. 2003). Hence, this 
necessitated an investigation of δ–ALA dependence on the production of P450_FG067 in E. 
coli. The recovered P450_FG067 was separated by gel electrophoresis to verify the 
expression of P450_FG067 with an expected size of 120 kDa. However, no signal for P450-
FG067 was detected. Moreover, supplementation with δ-ALA did not enhance the production 
of P450_FG067 (Figure 28). 
 . 
Figure 28: SDS-PAGE analysis of crude extract of E. coli DE3 cells after expression of P450-FG067(120 kDa)  
Lane 1: Marker, lane 6- P450_Fg0067_pET24a C43(DE3) E. coli – soluble protein after centrifugation without  
δ-ALA supplementation during cultivation, line 7 P450_Fg0067_pET24a C43(DE3) E. coli –insoluble protein 
fraction withut δ-ALA supplementation during cultivation, line 8- P450_Fg0067_pET24a C43(DE3) E. coli – 
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soluble protein after centrifugation with δ-ALA supplementation during cultivation, line 9 
P450_Fg0067_pET24a C43(DE3) E. coli – insoluble protein fraction after centrifugation with δ-ALA 
supplementation during cultivation MW of FG067: ~ 120 kDa. 
 
Additionally, a Western blot analysis was performed using anti-His-Tag. for P450_FG067 
(120 kDa) no signal was detected in the soluble and insoluble fractions of E. coli. However, 
one signal was detected with a size of approximately 65 kDa (Figure 29). 
 
Figure 29: Western blot of recombinant FG067 in E. coli 
Lane 1: Marker, lane 6- P450_FG0067_pET24a C43(DE3) E. coli –soluble proteins without δ-ALA 
supplementation during cultivation ,line 7 P450_FG0067_pET24a C43(DE3) E. coli –insoluble proteins without  
δ-ALA supplementation during cultivation, line 8- P450_FG0067_pET24a C43(DE3) E. coli –soluble proteins 
with δ-ALA supplementation during cultivation, line 9 P450_FG0067_pET24a C43(DE3) E. coli –insoluble 
proteins with δ-ALA supplementation during cultivation MW of FG067: ~ 120 kDa. 
 
The structural relatives of P450-FG067 were determined using the BLAST program. 
P450_FG0067 belong to the self-sufficient class of P450 monoxygenases. The entire 
polypeptide spans over 1069 amino acids, having two structural domains: N-terminal P450 
heme domain and the carboxyl-terminal half comprising 599 amino acid (~66 kDa), which is 
the FAD and FMN-NADPH-dependent reductase domain. The reductase domain allows the 
electrons to transfer from NADPH to the heme iron of the cytochrome P450 and is coded by 
the cysJ gene (Ostrowski et al. 1989) (Figure 30). 
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Figure 30: Conserved domains found by BLASTP suite for P450_FG067.  
 
The use of E. coli for the production of recombinant proteins can provide many 
practical problems. It has been alerady reported that E. coli is not suitable for the production 
of many large, complex proteins containing disulfide bonds, or proteins that require post-
translational modifications. Furthermore, the stability of foreign proteins produced in E. coli 
can be low due to proteolytic degradation, and overexpressed proteins are often produced in 
the form of inclusion bodies, which later require complicated and costly denaturation and 
refolding processes to make them functional (Rosano and Ceccarelli 2014). Protease-deficient 
bacterial strains (BL21 cells) did not decrease the proteolytic degradation of the recombinant 
enzyme. The P450-FG067 is 120 kDa and C-terminal His-tagged protein. The recombinant 
P450_FG067 was found to be partially degraded by the host-cell BL21(DE3). As shown by 
western immunoblot analysis, one major band of about 66 kDa was observed. It is possible 
that recombinant P450-FG067 expressed by E. coli was cleaved by a protease during the 
cultivation into two parts. The first one: FAD and FMN-NADPH-dependent reductase domain 
(~66 kDa), which is corresponding to the western-blot analysis shown in Figure 29 (C-
terminal. The second: P450 heme domain (N-terminal). Moreover, P450 content in different 
fractions (soluble and insoluble) was checked by carbon monoxide (CO)-difference spectrum 
analysis using a ferrous-CO assay, but with the maximum typical shift of absorption from 420 
nm to 450 nm was absent. That indicates that P450-FG067 was not successfully expressed in 
E. coli.  
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3.2.2 Expression and activity determination in P. pastoris 
P. pastoris has the ability to produce foreign proteins at high levels and to provide 
advanced protein folding pathways for heterologous proteins, such as glycosylation, disulfide 
bond formation and proteolytic processing. (Macauley-Patrick et al. 2005). Moreover, recent 
studies have reported the heterologous synthesis of fatty acids using P. pastoris as a host 
(Kim et al. 2014; Meesapyodsuk et al. 2015). Therefore, as a second host for the heterologous 
expression of eukaryotic P450s, P. pastoris has been chosen. Expression of any foreign gene 
in P. pastoris requires three basic steps: the insertion of the gene of interest into an expression 
vector; introduction of the expression vector into the P. pastoris genome; and examination of 
potential expression strains for the foreign gene product (Cereghino and Cregg 2000). The 
choice of the proper expression vector and complementary host strain are the most important 
prerequisite for successful recombinant protein expression. Since P450_FG067 is a large 
protein (~120 kDa), a pPICZ A vector was chosen for intracellular expression. The pPICZ A 
contains the Zeocin resistance gene for the positive selection in E. coli and P. pastoris. . The 
following P. pastoris strains were transformed by electroporation with the linearized 
pPICZ A-FG067 and plated on YPDS-agar containing Zeocin: BG10 (wild type), BG11 
(aox1Δ MutS) - slow methanol utilization derivative of PPS-9010 and protease deficient 
BG16 (pep4Δ, prb1Δ). The P450_FG067 was intracellularly expressed in all three P. 
pastoris strains, using batch cultivations with methanol pulses. The purified fractions were 
analyzed by SDS–PAGE as shown in Figure 31. 
 
Figure 31: SDS-PAGE analysis of crude cell extract and the purified fraction of P. pastoris BG10, BG11, BG16 
after expression of P450-FG067 (120 kDa). 
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Lane 1: Marker, lane 2- P450_Fg0067_pPICZ A BG10 P. pastoris – soluble protein after centrifugation ,lane 3 
P450_Fg0067_pPICZ A BG10 P. pastoris – purified fraction, lane 4- P450_Fg0067_pPICZ A BG11 P. pastoris 
– soluble protein after centrifugation, lane 5 P450_Fg0067_pPICZ A BG11 P. pastoris – purified fraction, lane 
6 P450_Fg0067_pPICZ A BG16 P. pastoris – soluble protein after centrifugation, lane 7 P450_Fg0067_pPICZ 
A BG16 P. pastoris – purified fraction MW of FG067: ~ 120 kDa. 
 
As shown in Figure 31, P450_FG067 was expressed in all P. pastoris strains. In contrast to E. 
coli, P. pastoris contains endogenous CYPs. This is not considered as a complication, since 
endogenous P450s appear in non-significant levels and are hardly detectable by CO-
difference spectroscopy (Lee et al. 2010). However, determination of P450 concentration in 
crude extract of P. pastoris was challenging. Therefore, only purified fractions were 
determined by the carbon monoxide (CO) difference spectrum assay. The typical shift of the 
maximum absorption from 420 nm to 450 nm was detected was observed only in the purified 
fraction of P450_FG0067_pPICZ_A P. pastoris BG10 strain. As shown in Figure 32, the 
reduced CO difference spectra, showed two distinct peaks at 420. Formation of the peak at 
420 is related to the denatured forms of P450, and the peak at 450 is specific to the active 
form of the cytochrome P450. This instability of the expressed P450 could be the result of  
improper extraction and purification. Based on the CO-difference spectra, the concentration of 
purified FG0067 was estimated to be equal to 0.16 µmol mL-1. 
 
Figure 32: CO binding analysis of purified P450-FG067 expressed in P. pastoris. 
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The efficiency of the electron transfer directly affects the overall rate of P450-
catalyzed reactions. Therefore, possibilities for the activity determination of the redox system 
has been investigated. Like the cytochrome P450 reductase, it is capable of transferring 
electrons not just to P450, but to artificial acceptors, such as cytochrome c (cyt c) and 2,6- 
dichlorophenolindophenol (DCIP) as well. These molecules serve as model substrates for the 
reductase activity determination. Here, a fast NADPH depletion was observed along with the 
conversion of dark blue DCPIP to its colorless reduced form. Based on the DCPIP assay, the 
activity of the electron transfer components was qualitatively measured, showing an active 
form of the reductase domain of cytochrome P450_FG067. After the concentration of 
P450_FG067 as well as the activity of the reductase domain were measured, P. pastoris BG10 
(wild type) strain was selected as the best expression strain for P450-FG067 for larger scale 
expression. Moreover, P450_FG0067 was successfully purified by IMAC from P. pastoris 
crude extract (Figure 33). 
 
Figure 33: SDS-PAGE of His-tag purification of recombinant FG067 
Lane1: Soluble fraction of cell crude extract from P. pastoris, lane 2: Marker, lanes 3-8: Elution of purified 
FG067, MW:FG067: ~ 120 kDa, CysJ~66 kDa, 35-40 kDa mADH. 
 
 
Molecular mass of the expressed P450_FG067 was calculated to be equal to 120 kDa. As 
determined by SDS-PAGE analysis (Figure 33), the protein was in part degraded and visible 
as 66 kDa (CysJ- which is the FAD and FMN-NADPH-dependent reductase domain) protein, 
similar as in the E. coli expression earlier (Figure 29). Moreover, the co-purified protein of 
approximately 35-40 kDa was identified as a typical P. pastoris intracellular protein. 
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According to Chen et al. it is most probably the mitochondrial alcohol dehydrogenase 
isozyme III (mADH), which exhibits a high binding affinity for Ni-IMAC (Chen et al. 2014).  
3.2.3 P450-FG067 as a fatty acid hydroxylase 
The whole-cell conversion system with P450-FG067 in P. pastoris has been tested for 
the ability to hydroxylate fatty acids such as capric acid (C10), lauric acid (C12), myristic acid 
(C14), palmitic acid (C16) and stearic acid (C18). Resting and growing whole cells are 
commonly used as biotransformation catalysts. The use of growing cells is considered more 
beneficial than resting-cells, when expressing a protein with low stability, since they permit 
sustained protein expression during biotransformation. However, resting cells have the 
advantage that the desired reaction can be tested regardless of growth and at higher cell 
densities. Moreover, the conditions for the biotransformation can be selected independently of 
growth conditions, minimizing side reactions and at the same time the identification of 
potential limitations (Liu et al. 2018). Differences between growing and resting cells on fatty 
acid hydroxylation rates were investigated. However, no significant difference was noted. 
Substrate specificity of P450_FG067 against saturated fatty acids was determined using 
different thin layer chromatography methods (Figure 34). The pPICZ A, an empty vector 
expressed in P. pastoris was used as a negative control. 
 
Figure 34: Fatty acid hydroxylation by whole-cell conversion system with P450-FG067 in P. pastoris. 
From left to right: 1 spot: capric acid (C10) control P. pastoris ; 2 spot: capric acid (C10) control FG067 P. 
pastoris; 3 spot: lauric acid (C12) control P. pastoris; 4 spot: lauric acid (C12) control FG067 P. pastoris; 5 spot: 
myristic acid (C14) control P. pastoris; 6 spot: myristic acid (C14) FG067 P. pastoris; 7 spot: palmitic acid 
(C16) control P. pastoris; 8 spots: palmitic acid (C16) FG067 P. pastoris; 9 spot: stearic acid (C18) control P. 
pastoris; 10 spot: stearic acid (C18) FG067 P. pastoris. 
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The experimental results of TLC have indicated that the P450_FG067 was able to 
unspecifically hydroxylate fatty acids such as capric acid, lauric acid, myristic acid, palmitic 
acid and stearic acid into corresponding hydroxy fatty acids (Figuer 35). Based on the results 
of TLC, GC-MS and HPLC analysis was performed. The MS analysis data can be found in 
the Appendix ( Figure A 11- Figure A 14). 
 
Figure 35: Reaction scheme of mono-hydroxylation of fatty acids by Fusarium graminarium cytochrome P450 
monooxygenase. P450-FG067 can hydroxylate capric acid (C10), lauric acid (C12), myristic acid (C14) and  
palmitic acid (C16) into their respective ω-1, ω-2 and ω-3 hydroxy fatty acids derivatives 
 
Analysis of the product profile and detailed characterization of hydroxylated fatty acid 
products were performed via gas chromatography–mass spectrometry (GC–MS). GC–MS 
analysis of the product mixtures resulting from FA conversions by P450-Fg067 revealed that 
the enzyme preferentially hydroxylated the inner carbon atoms of the FA chains and 
generated mono-hydroxylated products (Figure 35 and Table 1). The five FAs are 
unselectively hydroxylated at their inner chain carbon atoms, with the highest regioselectivity 
exhibited towards capric acid (62% hydroxylation in ω-1 position) and lauric acid (64% 
hydroxylation in ω-1 position). The conversion of fatty acids were estimated from the signal 
intensity on HPLC and shown in Table 1.  
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Table 1: The ratios of hydroxy fatty acids produced by P450 FG067 using capric acid (C10) lauric acid (C12) 
myristic acid (C14), palmitic acid (C16), stearic acid (C18) as substrates. The enzyme catalysis was allowed to 
proceed for 24 h. 
 
 
n.d.=not detected. 
3.2.4 Discussion 
Similarly to CYP505 (P450foxy), P450-FG067 catalyzes the subterminal (ω−1 to 
ω−3) hydroxylation of fatty acids (Nakayama et al. 1996). The product distribution for P450-
FG067 was substrate dependent with respect to the chain length of fatty acid. Capric acid was 
the most efficiently converted to ω−1to ω−3 hydroxy decanoic acids in the order of ω−1> 
ω−2 > ω−3, with a total product yield of 94%. The hydroxylation of lauric acid (C12) 
occurred primarily at the ω-1 position (64.9%) to hydroxylate at the ω-2 position (26.9 %) 
over ω-3 (8.2%). The biotransformation of myristic acid (C14) by P450-FG67 is of particular 
interest to predominantly give the ω-2 hydroxyacid (55.9%) with the ω-1 (44.1 %), and ω-3 
product was not detected. Moreover, P450-FG067 showed a slight preference of palmitic acid 
hydroxylation at the ω-1 position (44%) over ω-1 (42.4%) and ω-3 (13.7%) positions with a 
low total product yield of 8%.  
This study demonstrated the use of a self-sufficient fungal P450 as a biocatalyst to 
convert fatty acids to ω−1to ω−3 hydroxyl FAs. A critical issue with P450 enzymatic 
conversion is the electron transfer. More specifically, for catalytic activity P450s must be 
associated with redox partner proteins that transfer electrons from NAD(P)H to the P450 
heme center, which make P450 systems more complex (O’Reilly et al. 2011). By contrast, 
self-sufficient P450_FG067 overcomes these barriers because it does not require additional 
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redox partner. The P450-FG067 has a phylogenetically close relationship to P450foxy and 
P450BM3. The biotechnological importance of catalytically self-sufficient P450s, in 
particular the fatty acid hydroxylases, have already been well established (Kitazume et al. 
2000, 2008; Munro et al. 2002). Development of novel self-sufficient P450s opens up new 
horizons in the field of the synthesis of new molecules. Furthermore, the recombinant cell-
dependent system described herein does not require NADPH for bio-conversion. 
Recombinant P450foxy expressed in P. pastoris facilitates the hydroxylation of C10:0 to 
C16:0 fatty acids at the positions ω-1 to ω-3 (for C10:0 and C12:0 position ω-1 is most 
favored). The P450_FG067 can be applicable as biocatalysts in the production of hydroxy 
fatty acids in industry like other self-sufficient P450-BM3 or P450-foxy (Iliuta et al. 2015; 
Xiao et al. 2018).  
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3.3 Arginine kinase 
ArgK-encoded arginine kinase (EC 2.7.3.3) was selected for developing a biocatalytic 
production of Nω-phospho-L-arginine. 
3.3.1 Recombinant Expression and Purification of ArgK in E. coli 
The ArgK is one of the best-characterised arginine kinase and different crystal 
structures of the enzyme are available. Moreover, the isolation of ArgK-LP from biological 
sources such as horseshoe crab sperm or muscle would be both inefficient and uneconomic 
compared to the recombinant expression of this enzyme (Strong and Ellington 1993). The E. 
coli B strain is characterized protease deficiency, low acetate production at a high level of 
glucose. These properties make E. coli B a desirable host for the production of genetically 
engineered proteins. Moreover, E. coli BL21(DE3) carries a DE3 recombinant phage 
harboring the T7 RNA polymerase gene that can direct high-level expression of cloned genes 
under the control of the T7 promoter (Jeong et al. 2009). Since E. coli BL21(DE3) has been 
very widely used to express recombinant proteins, this strain of E .coli was chosen for 
expression of ArgK-LP. The 6xHis tag is small and does not usually interfere with protein 
function, for the production of pharmaceuticals and removal of the tag may be desired to 
obtain a protein with the native amino acid sequence. Several ways of removing N-terminal 
tags are available. The tag can be cleaved by an endoprotease, such as TEV (Booth et al. 
2018). Therefore, the designed construct containing TEV recognition site and coding 
sequence of ArgK-LP and the presence of a His-tag in the fusion facilitates protein 
purification by affinity chromatography. The arginine kinase was overexpressed as 
recombinant protein in E. coli BL21 (DE3) and the amount of the ArgK was examined on 
SDS-PAGE. The size of the expressed cytoplasmatic monomer was approximately 40 kDa 
(Figure 36) This result is similar to the isolated sperm ArgK as determined by Strong and 
Ellington (Strong and Ellington 1995). 
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Figure 36: SDS-PAGE of His-tag purification of recombinant ArgK 
Lane 1: Marker, lane 2: Soluble fraction of cell crude extract from E. coli BL21 (DE3), lane 3: Washing fraction, 
lane 4: Elution of purified ArgK, lane 5: desalted and purified protein fraction of ArgK, MW of ArgK: ~ 40 kDa. 
 
As the recombinant protein carried an N-terminal His-tag, ArgK was successfully 
purified by IMAC purification (Figure 35). Moreover, ArgK-LP was overexpressed in E. coli 
BL21 (DE3) as a soluble protein in high yield. Around 30% of the protein was localized in the 
soluble protein fraction of E. coli. The obtained yield of the purified ArgK was 24 mg L
-1
 of 
E. coli culture. In contrast, in a previous study by Strong et al., in which no codon-optimised 
gene was expressed, the concentration of soluble ArgK-LP was much lower (~3 mg L
-1
 of 
culture) and most of the recombinant protein was aggregated as insoluble and inactive protein 
(Strong and Ellington 1996). 
3.3.2 Arginine kinase activity determination and storage stability 
The activity of arginine kinase was determined by the pyruvate kinase/LDH assay 
following the procedures devised by Oliveira et al. using L-arginine as a substrate (Oliveira et 
al. 2001). The specific activity of purified protein was about 80 U mg
-1
 and the activity in the 
crude extract 834 U mL
-1
(Table 2). In addition, the specific activity of the recombinant ArgK-
LP in this study was also approximately 28 times higher than that reported by Strong and 
Ellington (Strong and Ellington 1996).   
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Table 2: Protein content and photometric activity determination of Arginine kinase 
Protein content: 1.68 mg mL
-1
 
Activity of cell crude extract (soluble fraction):                                  834 U mL
-1
 
The specific activity of purifiedArg4:                                             80 U mL
-1
 
 
The use of enzymes in industry is widely recognized because of their substrate specificity and 
green chemistry instead of harmful chemicals. However, their application has been hampered 
owing to their associated high costs and lack of stability under process conditions and storage 
(Martins et al. 2019). Knowledge of arginine kinase properties and behavior would allow 
optimizing conditions of its storage as well as formulating strategy towards its stabilization. 
The aim of this work was to study the enzyme activity and stability under different conditions 
and elaborate effective approaches towards its stabilization to verify the applicability of this 
enzyme for industrial use. Therefore, the stability of arginine kinase under storage conditions 
was investigated. Further, the influence of glycerol as a stabilizer was assayed. The activity of 
arginine kinase over one month in different formulations and storage temperatures (4ºC and -
20ºC) was investigated. The storage temperature and the addition of 30% glycerol had a 
positive influence on the enzyme activity. Without any precautions, a maximum loss of 40% 
was observed when ArgK-LP was stored at 4ºC. In a case where the crude extract of ArgK 
was freeze-dried, a maximum loss of 50% was determined. When glycerol was added, and 
Arg-LP was stored at -20ºC, only 13% loss of activity was detected (Figure 37).  
Results and discussion 
74 
 
 
Figure 37: Storage stability investigation of recombinant arginine kinase in different formulation.  
Arginine kinase activity measured in different enzyme formulations are shown as relative activities compared 
with the highest activity measured for fresh prepared soluble enzyme with 100% activity (white columns), 
respectively to activity of soluble enzyme stored over one month at 4°C (squared columns), soluble enzyme 
stored over one month at 4°C with additional of 30% glycerol ( dotted columns), soluble enzyme stored over one 
month at -20°C with additional of 30% glycerol (striped columns), freeze-dried arginine kinase (filled columns). 
The results ± standard deviations are means of three independent experiments, each set in triplicate. 
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3.3.3 Biocatalytic phosphorylation of L-arginine 
Since recombinant arginine kinase has been prepared in E. coli as a highly active and 
stabile enzyme, teodius five-step chemical synthesis reactions of Nω-phospho-L-arginine can 
be replaced by a straightforward one-step biocatalytic phosphorylation. The development of 
biocatalytic phosphorylations is strongly facilitated by direct 
31
P-NMR analysis of product 
formation in the reaction mixture. The simultaneous consumption of the phosphoenolpyruvate 
and the formation of the correct product is thereby an advantage and suitable reaction 
conditions can be easily developed. The time course of a biocatalytic Nω-phosphorylation of 
L-arginine was, therefore, followed by 
31
P-NMR spectroscopy as shown in Figure 37. The 
reaction was carried out at pH 8.0 and with ATP recycling by using the PEP/pyruvate kinase 
system with a slightly sub-equimolar amount of PEP. A slight excess of L-arginine compared 
with PEP was chosen to avoid incomplete transformation of the latter, which turned out to be 
challenging to separate from the arginine-phosphate. In contrast to
1
H-NMR spectra, the 
31
P-
NMR spectra are very clear and in time the signal increases (from bottom lane 1 to the top 
lane 7 in Figure 38A) at-3.65 ppm. This demonstrates the formation of the desired product -
Nω-phospho-L-arginine- whereas the decreasing signal at 0.80 ppm shows the consumption of 
PEP, in line with ATP turnover. The time required for complete conversion can be optimised 
by selecting the total activity of the arginine kinase utilised for the reaction. It is shown in 
Figure 38 B for phosphorylation completed within 24 h. The method turned out to be suitable 
for the synthesis of preparative quantities of Nω-phospho-L-arginine, whereby the use of crude 
extract of ArgK and purified ArgK gave similar results. 
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Figure 38. A) Reaction kinetics of biocatalytic phosphorylation of L-arginine; 
31
P-NMR spectra of a reaction 
mixture from t=0 (lane1) to t=5h (lane7); signal at 0.80 ppm: PEP; signal at -3.65 ppm: Nω-phospho-L-arginine. 
B) Time course of Nω-phospho-L-arginine product formation and PEP consumption during biocatalytic 
phosphorylation of L-arginine. 
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The biocatalytic procedure and the subsequent work-up to the pure product, which is 
Nω-phospho-L-arginine, have been successfully demonstrated and open up new opportunities 
for the selective biocatalytic N-phosphorylation of interesting low molecular weight’s 
compounds and metabolites. Moreover, biocatalytically produced Nω-phospho-L-arginine is 
already implemented in industry by the Merck company. 
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3.4 Shikimate kinase 
AroL-encoded type II shikimate kinase (EC 2.7.1.71) was selected for the 
development of a biocatalytic shikimic-3- phosphate production. 
3.4.1 Recombinant Expression and Purification of AroL in E. coli 
K12 is the most studied E. coli strain (K strain), E. coli BL21 (B strain) is the most 
used for recombinant protein production. The E. coli BL21 strain lack some proteases (e.g. 
Lon protease, key to eliminating unfolded proteins), achieve higher biomass yields and 
produces much less acetate than E. coli K12 (Pinske et al. 2011). Moreover, using E. coli as a 
host system for an expression of gene which origin from E. coli is a good choice. Herein, 
designed constructs to express shikimate kinase in E .coli BL21 harboring a N-terminal His-
tag fusion, which can be efficiently removed using the TEV protease is described. Employing 
the aroL gene from E. coli K12 (Uniprot P0A6E1, AROL_ECOLI), the shikimate kinase was 
recombinantly overexpressed in E. coli BL21(DE3) in a significant amount as a soluble 
protein, consisting of around 30% of total protein. The solubility of recombinant AroL from 
E. coli was similar to the solubility of recombinant shikimate kinase from Mycobacterium 
tuberculosis expressed in E. coli BL21(DE3) by Oliviera et al. (Oliveira et al. 2001). The 
recombinant His6-tagged AroL protein was purified on a Ni-IDA column. On the SDS-gel, a 
major band with a molecular weight of 20 kDa was observed and matched with the predicted 
mass of shikimate kinase (Figure 39).  
 
Figure 39.:SDS–PAGE of His-tag purification of recombinant AroL.  
Lane 1: marker; lane 2: soluble fraction of cell crude extract from E. coli BL21 (DE3); lane 3: washing fraction; 
lane 4: elution of purified AroL; and lane 5: desalted and purified protein fraction of AroL, MW of AroL: 20 
kDa. 
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3.4.2 Shikimate kinase activity determination and storage stability 
The protein content (determined with the BCA assay) of the purified AroL was 1.47 
mg mL
-1
 and the obtained yield of the purified AroL was 40 mg L
-1
 of E. coli culture. 
Shikimate kinase enzyme activity was determined at 25ºC and pH 7.5 spectrophotometrically 
by measuring the oxidation of NADH at 340 nm, based on ADP release by a coupled assay 
with pyruvate kinase and lactate dehydrogenase (LDH), according to Millar et al. (Millar et al. 
1986). The specific activity of the purified recombinant AroL 41 U mg
-1
 with a total yield of 
39 400 U L
-1
. The activity of shikimate kinase obtained in the crude extract was 788 U mL
-1
 
(Table 3).  
 
Table 3: Shikimate kinase activity of cell crude extract (soluble fraction), AroL protein content, and shikimate 
kinase activity of the purified protein. Activity of cell crude extract (soluble fraction) 788 U mL
-1
 Activity a) of 
purified AroL 41 U mg
-1
 Protein content of purified AroL 1.47 mg mL
-1
 
Activity of cell crude extract (soluble fraction) 788 U mL
-1
 
Activity of purified AroL: 41 U mg 
-1
 
Protein content of purified AroL 1.47 U mL
-1
 
 
Interestingly, the activity and the yield of recombinantly produced shikimate kinase is 
higher than that of shikimate kinases isolated from E. coli, Bacillus subtilis, Spinacia 
oleracea, Oryza sativa or Sorghum bicolor. It has been concluded that the stability of an 
enzyme is essential for its application in industry. Therefore, the activity of the recombinant 
shikimate kinase AroL has been measured in different formulations and at the storage 
temperatures of 4ºC and 20ºC over the period of 1 month. Glycerol when used as a 
cryoprotectant gives good results (Iyer and Ananthanarayan 2008). Addition of 30% glycerol 
and the storage temperature had only a slight influence on the enzyme activity. Moreover, 
AroL can also be stored as a powder without any precautions, as we observed only 30% loss 
of starting activity during lyophilisation (Figure 40). 
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Figure 40: Shikimate kinase activity measured in different crude enzyme formulations are shown as relative 
activities as compared to the activity of the freshly prepared soluble enzyme fraction, which was set to 100% 
activity (white columns): relative activity of soluble AroL stored for over 1 month at 4ºC with no addition 
(squared columns), soluble enzyme AroL with addition of 30% glycerol stored for over 1 month at 4 C (dotted 
columns), soluble enzyme stored for over 1 month at 20ºC with addition of 30% glycerol (striped columns), 
freeze-dried shikimate kinase (filled columns). The results standard deviations are means of three independent 
experiments, each measured in triplicate. 
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3.4.3 Biocatalytic phosphorylation of Shikimic acid 
In contrast to the tremendous chemical efforts involved in the proof of the right 
shikimate-3-phosphate structure, formation of shikimate 3-phosphate can now be easily 
identified by NMR spectroscopy. As shown below by the NMR-spectra of the selective 
shikimate kinase-catalyzed monophosphorylation of shikimic acid in the 3- position (Figure 
41).  
 
Figure 41: Typical time course of shikimate kinase-catalyzed phosphorylation of shikimic acid from a series of 
seven experiments under different reaction conditions (n¼1) measured by A) 1H-NMR, signals at 6.40 and 6.36 
ppm: H-C(2) ofproduct and substrate, respectively; signals at 5.30 and 5.11 ppm: PEP; B) 
31
P-NMR, signal at 
3.84 ppm (d): shikimic acid 3-phosphate; signal at -1.01 ppm (s): PEP 
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The 
1
H-NMR spectra thereby show that with the time course of the phosphorylation (from the 
start at the bottom lane 1 to the time point t ¼ 12 h at the top lane 10 in Figure 40A), the 
signal at 6.36 ppm of H-C(2) of the substrate decreases and the signal at 6.40 ppm of H-C(2) 
of the product increases. If the same reaction was analyzed by 
31
P-NMR, the increase of the 
doublet signal with increasing time (from the start at the bottom lane 1 to the time point t ¼ 
12 h at the top lane 10 in Figure 44B) at 3.84 ppm would show the desired product shikimate 
3-phosphate, while the signal decrease at 1.01 ppm would show the concomitant 
phosphoenolpyruvate consumption for the ATP cofactor regeneration. 
Moreover, reaction conditions for shikimic acid phosphorylation can be developed 
rapidly, as demonstrated by the time course of the conversion to shikimic acid 3-phosphate 
within less than 100 min in Figure 42. The AroL catalyzed synthesis was carried out at pH 7 
using the phosphoenolpyruvate (PEP)/ pyruvate kinase(PK)-system for ATP recycling. As 
demonstrated in Figure 42, the phosphoryl-donor PEP is thereby completely consumed, which 
is relevant for facilitating product purification. 
 
 
Figure 42: Typical reaction, monitoring of the AroL-catalyzed phosphorylation of shikimic acid by 
31
P-NMR 
showing the increase of shikimic acid-3-phosphate (red curve) and the decrease of phosphoenolpyruvate (blue 
curve). 
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3.4.4 Discussion 
The chemical synthesis of shikimic acid-3-phosphate has been described as the tedious 
multi-step procedure, which require the introduction and removal of protecting groups and 
involve reagents/solvents with safety, health, and environment issues (Bartlett and Mcquaid 
1984). Biocatalytic phosphorylation of shikimate in the 3-position overcomes the problems 
associated with the chemical processes for the synthesis of this commercial valuable 
metabolite. The production of the highly active and stable recombinant E. coli K12 shikimate 
kinase AroL has been achieved by synthesizing the codon-optimized aroL gene and 
expressing it in high yield in E. coli BL21. The recombinantly expressed shikimate kinase has 
been applied in the ATP-dependent phosphorylation of shikimic acid, which was coupled with 
the pyruvate kinase-catalyzed ATP regeneration to avoid inhibition by ADP. The time course 
of the highly selective phosphorylation of shikimate in the 3-position was investigated by 
1
H- 
and 
31
P-NMR. This has facilitated the development of an efficient biocatalytic one-step 
synthesis at multi-gram scale of shikimic acid-3-phosphate, which after a standard workup 
procedure could be prepared in >97% purity and with a yield of the isolated pure lithium salt 
of 53%. Additionally, the highly active and stable shikimate kinase enables rapid access to 
other, various phosphorylated shikimate analogues and expands the platform for the 
biocatalytic phosphorylation of metabolites (Wohlgemuth et al. 2017). Moreover, the 
enzymatic phosphorylation of shikimic acid in the 3-position and the subsequent workup has 
been scaled up to multi-gram scale and it is already implemented in industry by Merck 
company. 
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3.5  Argininosuccinate lyase (ASL) 
Arg4-encoded argininosuccinate lyase (EC 4.3.2.1) was selected for developing a 
biocatalytic procedure for the synthesis of L-argininosuccinate. 
3.5.1 Recombinant Expression and Purification of ASL in E. coli 
Since E. coli BL21 is the most used for recombinant protein production, herein, 
designed construct to express argininosuccinate lyase in E. coli BL21 harboring a N-terminal 
His-tag fusion, which can be efficiently removed using the TEV protease was used. 
Employing the arg4 gene from Saccharomyces cerevisiae (Uniprot P04076, ARLY_YEAST), 
argininosuccinate lyase was recombinantly overexpressed in E. coli BL21 (DE3). The 
argininosuccinate lyase was overexpressed in E. coli as a soluble protein in high yield, i.e. 
around 50% of the protein was localized in the soluble protein fraction of E. coli. As an active 
enzyme, ASL is a tetramer, composed of four active sites. The size of one monomer is 
approximately 52 kDa, as determined by SDS-PAGE analysis (Figure 43). Since the 
recombinant protein carried an N-terminal His-tag, ARG4 was successfully purified by IMAC 
purification (Figure 43). The obtained yield of the purified ARG4 was 20 mg L
-1
 of E. coli 
culture. 
 
Figure 43: SDS-PAGE of His-tag purification of recombinant ARG4. 
Lane 1: Marker, lane 2: Soluble fraction of cell crude extract from E. coli BL21(DE3), lane 3: Flow-through, 
lane 4: Washing fraction, lane 5-9: Elution of purified ASL,  MW of ASL: ~ 52 kDa 
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3.5.2 Argininosuccinate lyase activity determination and storage stability 
The activity determination of argininosuccinate lyase was based on the production of 
fumarate by to Kuchel et al. (Kuchel et al.1975). The specific activity was about 20 U mg
-1
 of 
purified protein and 206 U mL
-1
 in the crude extract (Table 4). In contrast to this, the specific 
activity of argininosuccinate lyase purified from Saccharomyces cerevisiae crude extract was 
much lower, only 0.081 U mg
-1
. 
 
Table 4. :Arg4 protein content, the activity of cell crude extract (soluble fraction) and activity of purified protein 
Protein content: 0.92 mg mL
-1
 
Activity of cell crude extract (soluble fraction): 206 U mL
-1
 
Activity of purified ASL: 20 U mg
-1
 
Commercial enzyme products are usually formulated in aqueous solutions or dry 
products. Both liquid and dry preparations must be formulated with the final application in 
mind. It is important for both the producer and customer to take into account storage stability 
requirements such as stability of enzyme activity. Therefore, employing argininosuccinate 
lyaseas as a biocatalyst in industry, the stability of the enzyme over one month in different 
formulations and storage temperatures (4°C and -20°C) was studied. The storage temperature 
and the addition of 30% glycerol had no influence on the enzyme activity. Hence, the 
argininosuccinate lyase, ARG4, can be stored as powder as well as crude extract (at 4°C) 
without any precautions (Figure 44). 
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 Figure 44:Activity of different formulations of argininosuccinate lyase. 
3.5.3 Biocatalytic synthesis of the pure metabolite N-(([(4S)-4-amino-4-
carboxybutyl] amino)iminomethyl)- L-aspartic acid as its lithium salt   
To evaluate the enzyme activity under reaction conditions, the biocatalytic Michael 
addition reaction was analyzed as a function of time directly in the NMR tube. 
1
H-NMR 
signals at 4.17 ppm (proton at the newly formed asymmetric carbon atom on the succinate 
portion) and 6.44 ppm (fumarate protons) were used for diagnosis of the reaction progress 
Figure (45A). 
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Figure 45:A: NMR of the biocatalytic Michael addition reaction of L -arginine to fumarate in D2O. 
1
H-NMR 
signals at 2.75 and 2.43 ppm show a too small integral due to insertion of deuterium from the solvent (D2O). B 
Time course of a biocatalytic Michael addition reaction using a solution of 50 μmol fumarate, 100 μmol L-
arginine in 1 mL D2O, adjusted to pH 7.5 with NaOH and 20 μl argininosuccinate lyase (ASL) solution (soluble 
fraction). 
 
Enzyme activity of roughly 4 U mL
-1
 was calculated for the cell crude extract (soluble 
fraction) from the fumarate turnover rate during the first 5 hours of the reaction. The time 
course of the biocatalytic Michael addition reaction could be seen from the increase of the 
1
H-
NMR-signal for the proton at the asymmetric succinate carbon and the decrease in the 
1
H-
NMR-signal for the olefinic protons of fumarate (Figure 45B). 
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3.5.4 Discussion 
For the first time, a simple and straightforward biocatalytic asymmetric Michael 
addition reaction was established for the synthesis of the key metabolite N-(([(4S)-4-amino-4-
carboxybutyl] amino)iminomethyl)-L-aspartic acid due to its lithium salt (L-argininosuccinic 
acid lithium salt), with 70% yield (based on the isolated pure product) and excellent purity. 
This one-step addition reaction was developed by running part of the urea cycle in reverse. 
Moreover, lyases are still unexplored class of enzymes, therefore, the use of the 
argininosuccinate lyase and reaction monitoring by NMR has enabled the development of a 
biocatalytic asymmetric Michael addition reaction as a novel green chemistry route with high 
molecular economy for the synthesis of this important metabolite at gram scale. This not only 
provides a straightforward one-step route to L-argininosuccinic acid lithium salt without side-
products, but also opens excellent future opportunities for utilising biocatalytic asymmetric 
Michael addition reactions for simple synthetic routes with high molecular economy to 
complex metabolites by the use of simple building blocks. 
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4 Summary and conclusions 
The definition of Green Chemistry was first formulated at the beginning of the 1990s – 
30 years ago and states as follows: “design of chemical products and processes to reduce or 
eliminate the use and generation of hazardous substances” (Poliakoff et al. 2002). Biocatalysis 
is one of the examples of “green” chemistry as it is relying on natural or modified enzymes. 
Today, biocatalysis is a standard technology for the production of chemicals (Straathof et al. 
2002).  
In this PhD thesis, the implications of biocatalysis using different class of enzymes are 
discussed: two cytochrome P450 monoxygenases, two kinases and one lyase are shown as 
tools for the production of bioactive compounds. 
The P450 enzymes have a central role in the oxidative metabolism of a wide variety of 
compounds including the synthesis of endogenous substrates such as steroids and fatty acids. 
Moreover, P450s catalyze the hydroxylation of non-activated carbon atoms in a regio- and 
stereospecific fashion avoiding use of protecting groups and several, time-consuming 
chemical steps.  
Here, the recombinant expression and biocatalytic characterization of bacterial 
CYP107D1 for the regio- and stereoselective hydroxylation of two steroid compounds is 
reported. Since the natural electron transfer partners of these P450s are unknown, PdX and 
PdR from P. putida were employed to supply CYP107D1 with the necessary electrons for 
catalysis. This three-component system was used in bioconversions of two bile acids: LCA 
and DCA. P450 CYP107D1 exhibits high regio- and stereoselectivity for the tested steroids, 
giving 6β-hydroxylated products. The properties of the CYP107D1 make this multifaceted 
P450 monooxygenase an attractive enzyme for the production of novel drug metabolites. 
Moreover, the crystal structure of the enzyme is known, which provides the basis for 
developing a protein-engineering strategy aimed at catalytic properties of the CYP107D1 
The second enzyme described in the thesis is the self-sufficient cytochrome P450 
monooxygenase from Fusarium graminarium (FG067). From the overall structure, it 
resembles the well investigated CYP102 from Bacillus megaterium (CYP BM3) and the P450 
from Fusarium oxysporum (CYPfoxy). In this study, two different strategies to recombinantly 
produce the fungal P450 monooxygenase P450-FG067, namely (a) producing in E. coli and 
(b) producing in P. pastoris were investigated. The P450 FG_067 from Fusarium 
graminarium was successfully overexpressed in P. pastoris. The enzyme was functionally 
active, converted fatty acid substrates of carbon chain length C10-16 with regiospecificity of 
the hydroxylating position ω -1, ω - 2 and ω-3, with the highest affinity for capric acid. The 
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hydroxylation at different positions of the fatty acid chain is needed for different chemical 
industries. For example, ω-HFAs can be used as starting materials for the synthesis of 
polymers, with high resistance to heat or chemicals (Xiao et al. 2018). Therefore, the 
application of recombinant enzyme such as self-sufficient P450 FG_067 for a commercial 
production of HFAs is in high industrial demand. 
In this thesis, two kinases were used for the producton of phosphorylated metabolites. 
Kinases catalyzing N-phosphorylation, which are of synthetic interest because of tedious 
chemical procedures in selective chemical N-phosphorylations. A highly active and stabile 
arginine kinase, obtained by cloning and expressing the argK gene from Limulus polyphemus 
in E. coli, was used in the one-step synthesis of Nω-phospho-L-arginine using the 
phosphoenolpyruvate/pyruvate kinase system for ATP regeneration. Applying arginine kinase 
in biocatalysis opens up new opportunities for the selective biocatalytic N-phosphorylation of 
interesting low-molecular-weight compounds and metabolites. 
Another kinase investigated in this thesis was shikimate kinase. The highly active and 
stable shikimate kinase AroL was achieved by synthesizing the codon-optimized aroL gene 
and expressing it in high yield in E. coli. Next, shikimate kinase was used in an one-step 
synthesis of shikimate-3-phosphate using the phosphoenolpyruvate/pyruvate kinase system 
for ATP regeneration. Development of the described biocatalytic preparation of shikimate-3-
phosphate is a superior route incomparison to a tedious multi-step and low yield classical 
synthesis of this compound. The biocatalytic phosphorylation is of great interest for a 
commercial production of metabolites and metabolite-like structures.   
The last investigeted enzyme in this PhD thesis was argininosuccinate lyase from 
Saccharomyces cerevisiae. The argininosuccinate lyase was cloned and overexpressed in E. 
coli as a highly active and stable biocatalyst. A simple and straightforward biocatalytic 
asymmetric Michael addition reaction has been established for the synthesis of the key 
metabolite N-(([(4S)-4-amino-4-carboxybutyl]amino)imino methyl)-L-aspartic acid, 
commonly referred to as L-argininosuccinate. This one-step addition reaction was developed 
by running part of the urea cycle in reverse. The use of this argininosuccinate lyase and 
reaction monitoring by NMR enabled the development of a biocatalytic asymmetric Michael 
addition reaction as a novel green chemistry route with high molecular economy for the 
synthesis of this important metabolite at gram scale.  
Recent advances in the field of scientific research have helped to understand the 
structure and functional activities of enzymes, which has in turn led to an increase in their 
stability, activity and substrate specificity. Nowadays, biocatalysis  provide more sustainable, 
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efficient, and less polluting methods for the production of fine chemicals and advanced 
pharmaceutical intermediates. The biocatalysts used in this thesis are introduced as a 
technology for the efficient synthesis of biologically active compounds, which is greener, 
reduces pollution and costs compared to chemical synthesis. In summary, the pharmaceutical 
industry should use the advantage of the progress of biochemistry to obtain biocatalysts in the 
production of fine chemicals on an industrial scale, improving the quality of end products and 
saving costs. 
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5 Materials  
5.1 Chemicals and consumables 
Unless stated differently, all chemicals and consumables were purchased from the commercial 
suppliers ABCR (Karlsruhe), Fischer Scientific (Schwerte), Greiner (Solingen), Roth GmbH 
(Karlsruhe), Sarstedt (Nümbrecht), Sigma-Aldrich (Taufkirchen), StarLab (Ahrensburg) and 
VWR (Darmstadt) and used without further purification. 
5.2 Enzymes 
Table 5: List of used enzymes 
Enzyme Supplier 
SacI  New England BioLabs® Inc. (Ipswich, USA) 
BamHI  New England BioLabs® Inc. (Ipswich, USA) 
HindIII New England BioLabs® Inc. (Ipswich, USA) 
OptiTaq  Roboklon (Berlin, Germany) 
Taq Roboklon (Berlin, Germany) 
Lyticase from Arthrobacter luteus Sigma-Aldrich (Steinheim, Germany) 
 
5.3  Oligonucleotides 
All used oligonucleotides were synthesized by Thermo Fisher Scientific (Waltham, USA). 
Table 6: List of primer used for sequencing 
Primer Sequence (from 5’ to 3’) Purpose 
5´ AOX1 GACTGGTTCCAATTGACAAGC Sequencing recombinant 
P. pastoris clones 
3´ AOX1 GCAAATGGCATTCTGACATCC  
 
Table 7: List of primer used for subcloning (fw – forward, rev – reverse). 
Primer Sequence (from 5’ to 3’) Purpose 
E15_FW CGCGGATCCATGGCTGAGAG
TGTCCCTATC 
 
Primers used for the cloning 
approach to construct the 
pET24a_P450_FG067 plasmid E16_RV CCCAAGCTTGTCAAAAACGTC
AGTGGCAA 
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5.4 Strains 
For recombinant expression of proteins, E. coli and P. pastoris strains of different species 
were used (Table 10). 
Table 8: Strains 
5.5 Genes and plasmids 
5.5.1 Monooxygenase P450 (Olep) and putidaredoxin reductase (CamA) 
and putidaredoxin (CamB) 
E. coli C43(DE3) (Lucigen) was used for expressions. Plasmid pACYCcamAB for 
coexpression of putidaredoxin reductase (CamA) and putidaredoxin (CamB) from 
Pseudomonas putida were kindly provided by Anett Schallmey (Braunschweig University of 
Technology Department of Bioinformatics and Biochemistry). For gene synthesis of 
CYP107D1 (OleP), the nucleotide sequence of CYP107D1(OleP) was derived from the amino 
acid sequence published by Rodriguez (Rodriguez et al. 1995). This gene (GenBank: Q59819) 
was purchased from GenScript and already cloned into the final expression vector (pET28a 
(+) CYP107D1- Figure 46). 
Species Strain Genotype Supplier 
Escherichia coli DH5α 
supE44 _lacU169(F80lacZ_M15) hsdR17 
recA1 endA1 gyrA96 thi-1 relA1 
Clontech 
Escherichia coli -  BL21 (DE3) F
-
ompT gal dcm lon hsdSB(rB-mB-) λ(DE3 
[lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) 
Novagen 
Escherichia coli  TOP10  F
-mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80dlacZΔM15 ΔlacX74 nupG recA1 araD139 
Δ(ara-leu)7697 galE15 galK16 rpsL(StrR) 
endA1 fhuA2 λ- 
Invitrogen 
Escherichia coli NEB 5-alpha F
-φ80dlacZΔM15 Δ(lacZYA-argF) U169 end 
A1 recA1 hsdR17 (rk
-
, mk
+
)supE44λ- thi-
1gyrA96relA1 phoA 
New England 
Biolabs 
Escherichia coli C41(DE3) F –ompT hsdSB (rB- mB-) gal dcm(DE3) Lucigen 
Pichia pastoris BG10 wild type atum.bio 
Pichia pastoris BG11 BG11, aox1Δ (MutS) atum.bio 
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Figure 46: Vector card of pET28_CYP107D1 
5.5.2 Monooxygenase P450_FG067 
The putative cytochrome P450 gene sequence of Fusarium graminarium was obtained from 
the Fungal Cytochrome P450 Database. One of the synthetic genes was codon-optimised for 
E. coli and equipped with a C-terminal 6x-his-tag. The gene was synthesised and subcloned 
into pET24a(+) via NotI and XhoI by Genscript XhoI (USA), giving vector pET24a(+) 
_P450-FG067 (Figure 47). The second synthetic gene was codon-optimised for P. pastoris 
and equipped with a C-terminal 6x-His-tag. The gene was synthesised and subcloned into 
pPICZ A via EcoRI and NotI by Genscript (USA), giving vector pPICZ(A)_P450-
FG067(Figure 48). 
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.  
Figure 47: Vector card of pET24a_FG67 
 
Figure 48: Vector card of  pPICZ(A)_P450_FG067 
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5.5.3 Arginine kinase 
The arginine kinase gene ArgK was derived from Limulus polyphemus (ArgK-
LP;UniProtKB:P51541) as described by Strong and Ellington (Strong and Ellington 1995). 
The synthetic gene was codon-optimized for E. coli and equipped with an N-terminal 6-His-
tag and aTEV (tobacco etch virus) protease cleavage site for optional removal of the affinity 
tag. The gene was synthesised and subcloned into pET24a(+)via NdeI and NotI by Genscript 
(USA), giving vector pET24His(TV)-Karg-LimPo(op) (Figure 49). 
 
Figure 49: Vector card of pET24His(TV)-Karg-LimPo(op) 
5.5.4 Shikimate kinase 
The shikimate kinase gene aroL was derived from E. coli K12 (UniProtKB: P0A6E1) 
as described by Millar et al. (Millar et al. 1986). The synthetic gene was codon-
optimised for E. coli and equipped with an N-terminal 6-His-tag and a TEV protease 
cleavage site for optional removal of the affinity tag. The gene was synthesised and 
subcloned into pET24a(+) via NdeI and NotI by Genscript (USA), giving vector 
pET24-His(TV)-AroL-E.coli(op) (Figure 50). 
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Figure 50: Vector card of pET24-His(TV)-AroL-E.coli 
5.5.5 Argininosuccinate lyase  
The argininosuccinate lyase gene Arg4 was derived from Saccharomyces cerevisiae (strain 
ATCC 204508 / S288c) (UniProtKB: P04076) as described by Beacham and coworkers.
 
The 
synthetic gene was codon-optimised for E. coli and equipped with an N-terminal 6x-His-tag 
and a cleavage site TEV protease for optional removal of the affinity tag. The gene was 
synthesised and subcloned into pET24a(+) via NdeI and NotI by Genscript (USA), giving 
vector pET24-His(TV)-Arg4-Ecoli(op)( Figure 51). 
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Figure 51: Vector card of pET24-His(TV)-Arg4-Ecoli(op) 
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5.6 Media, additives and inducers 
Table 9: Media recipes used for liquid cultures. 
Medium, buffer or solution Components and preparation 
Lysogeny Broth medium/LB medium 
1% (w/v) NaCl 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
Filled with dest. water and sterilized in autoclave 
at 121°C for 21 min 
LB-SOC medium 
Addition of 10% (v/v) of 10 x SOC solution to 
sterile LB medium 
10X SOC solution 
0.2% (w/v) KCl 
2.0% (w/v) MgCl2 
2.0% (w/v) MgSO4 
4.0% (w/v) glucose 
Terrific Broth medium/TB medium 
12% Casein, enzymatically digested  
24% Yeast extract  
12.54 g L
-1
 K2HPO4 
2.31 g L
-1
 KH2PO4 
YPD-Medium  
1% (w/v) Yeast extract  
2% (w/v) Peptone 
Filled with dest. water and sterilized in autoclave 
at 121°C for 21 min. 
10% (v/v) 10x D solution  added 
10x D Solution 20% (w/v) Glucose, sterile filtered 
YPDS-Medium  
1% (w/v) Yeast extract 
2% (w/v) Peptone  
1 M Sorbitol  
sterilized in autoclave at 121°C for 21 min 
10% (v/v) 10x D Solution added 
BMGY-Medium  
1% (w/v) Yeast extract 
2% (w/v) Peptone 
1% (v/v) Glycerine 
sterilized in autoclave at 121°C for 21 min 
10% (v/v) Phosphate Buffer (1 M, pH 6.0), sterile 
filtered 
0,2% (v/v) 500x B-Solution added 
500x B-Solution 0,02% (w/v) Biotin, sterile filtered 
Materials  
 
100 
BMMY-Medium  
1% (w/v) Yeast extract  
2% (w/v) Pepton  
sterilized in autoclave at 121°C for 21 min 
10% (v/v) Phosphate Buffer (1 M, pH 6,0), sterile 
filtered 
0,2% (v/v) 500x B-Solution 
0,5% (v/v) Methanol added 
In order to create agar plates, the above mentioned liquid media recipes were used and 15% (w/v) agar-agar was 
added to the solution before autoclaving. When agar plates with antibiotics were prepared, the corresponding 
antibiotic was added to the adequate concentration after the LB-agar solution had cooled down to 40°C. 
 
Table 10: Recipes for concentrated used antibiotic and inductor stock solutions. 
Antibiotic/inductor/Additives Components and preparation 
Ampicillin (Amp)  Standard solution: 100 mg mL
-1
 in water,  sterile filtered 
Kanamycin (Kan)  Standard solution: 50 mg mL
-1
 in water, sterile filtered 
Chloramphenicol Standard solution: 50mg mL
-1
 in 95% EtOH, sterile filtered 
Zeocin (Zeo) Standard solution: 100 mg mL
-1
 in H2O , sterile filtered 
IPTG  Standard solution: 0.1 M in water, sterile filtered 
δ-Ala Standard solution: 0.1 M in water, sterile filtered 
Methanol 100% 
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5.7 Buffers and solutions 
5.7.1 General buffers 
Table 11:  Genereal buffers and solution recipes 
Buffer / solution Components and preparation 
50 mM sodium phosphate buffer pH 7.5 
14,99 g/l NaH2PO4 x 12 H2O 
1,13 g/l Na2HPO4 x 7 H2O 
100 mM Phosphate buffer pH 6.0  
13.2 mL 1M K2HPO4 
86,8 mL 1 M KH2PO4 
The combined 1 M stock solutions are diluted to 1000 
mL with dest. water and pH is adjusted to 7.4 if 
necessary. The buffer was sterilized if needed. 
Phosphate buffer of lower strength was prepared to 
dilute this concentration with dest. water and adjusting 
the pH 
100 mM Phosphate buffer pH 7.4 
80.2 mL 1M K2HPO4 
19,8 mL 1 M KH2PO4 
The combined 1 M stock solutions are diluted to 1000 
mL with dest. water 
 and pH is adjusted to 7.4 if necessary. The buffer was 
sterilized if needed. Phosphate buffer of lower strength 
was prepared to dilute this concentration with dest.  
water and adjusting the pH 
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5.7.2 Chemical Competent E. coli cells 
Table 12: Buffers and solution recipes needed for the preparation of chemical competent E. coli cells 
Buffer /solution Components and preparation 
Buffer RF1 
100 mM RbCl 
50 mM MnCl2 
30 mM CH3COOK 
10 mM CaCl2 
15% (v/v) glycerol 
pH is adjusted to 5.8 with 0.2 M acetic acid, and 
the solution is sterilised by filtration (0.2μm 
diameter). 
Buffer RF2 
10mM RbCl 
75 mM CaCl2 
10 mM 3-(N-morpholino) propane sulfonic acid 
15% (v/v) glycerol 
The pH is adjusted to 6.8-7.0, and the solution is 
sterilized by filtration (0.2 μm diameter).  
 
5.7.3 Electrocompetent P. pastoris cells 
Table 13: Buffers and solution recipes needed for the preparation of electrocompetent P. pastoris cells. 
Buffer / solution Components and preparation 
Sorbitol solution 
1M Sorbitol in water, filter sterile 
2M Sorbitol in water, filter sterile 
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5.7.4 Agarose gel electrophorese 
Table 14: Buffers and solution recipes needed for agarose gel electrophorese. 
Buffer / solution Components and preparation 
Agarose gel solution 
1 g agarose in 100 mL  
1x TAE buffer, dissolved by heating in microwave 
oven, per 50 mL gel 3 µL RotiStain (Carl Roth, 
Karlsruhe) were added for visualization under UV 
light 
Agarose gel loading Buffer 
30% (v/v) Glycerol 
25 mM EDTA 
0,25% (w/v) Bromophenol  
TAE-buffer (1x)  
40 mM Tris  
20 mM  Acetic acid  
2 mM EDTA (pH adjusted to 8.3) 
5.7.5 Protein purification 
Table 15: Buffers used for purification with IMAC using hand columns 
Buffer Components and preparation 
Equilibration/Wash buffer  
50 mM sodium phosphate buffer pH 7.5 
500 mM NaCl 
Elution buffer 
50 mM sodium phosphate buffer pH  
7.5500 mM NaCl 
300 mM Imidazole 
Column cleaning and storage solution 20% ethanol 
 
 
Table 16: Buffers used for  purification with IMAC using AKTA 
Buffer Components and preparation 
Equilibration/Wash buffer  
50 mM sodium phosphate buffer pH 7.5 
500 mM NaCl 
30 mM Imidazole 
Elution buffer 
50 mM sodium phosphate buffer pH 7.5 
500 mM NaCl 
500 mM Imidazole 
Column cleaning and storage solution 20% ethanol 
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5.7.6 SDS-PAGE 
Table 17: Buffers and solution recipes needed for SDS-PAGE. 
Buffer Components and preparation 
4 x Upper Tris 
0.5 M Tris-HCl pH 6.8  
0.4% (w/v) SDS 
4 x Lower Tris 
1.5 M Tris-HCl pH 8.0  
0.4% (w/v) SDS 
Acrylamide solution 
30% (w/v) acrylamide-,  
bisacrylamide solution (37.5:1) 
APS solution 
10% (w/v) ammonium persulfate solution in dest. 
Water 
Coomassie blue -staining solution 
0.1% (w/v) Coomassie Brilliant Blue G250 
30% (v/v) ethanol 
10% (v/v) acetic acid 
Filled with dest. water 
Coomassie blue- destaining solution 
30% (v/v) methanol 
10% (v/v) acetic acid 
Filled with dest. Water 
10 x SDS-Running buffer 
30.3 g Tris 
144 g glycerol 
10 g SDS 
Filled with dest. water, pH adjusted to 8.4 
SDS- Sample buffer 
20% (w/v) glycerol 
6% (w/v) 2-mercaptoethanol 
0.0025% (w/v) bromophenol blue 
Filled with 1 x Upper Tris 
Resolving gel 
2 mL 4 x Lower Tris 
3.33 mL acrylamide solution 
2.67 mL dest. water 
40 μL APS 
4μL TEMED 
Stacking gel 
1 mL 4 x Upper Tris 
520 μL acrylamide solution 
2.47 mL dest. water 
40 μL APS 
4 μL TEMED 
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5.7.7 Western blot 
Table 18: Buffers and solution recipes needed for western blot. 
Buffer Components and preparation 
Laemmli 2X buffer/loading buffer 
4% SDS 
10% 2-mercaptoethanol 
20% glycerol 
0.004% bromophenol blue 
0.125 M Tris-HCl 
pH and adjusted to 6.8 
Running buffer  
25 mM Tris base 
190 mM glycine 
0.1% SDS 
pH and adjusted to 8.3 
Transfer buffer (wet) 
25 mM Tris base 
190 mM glycine 
20% methanol 
pH and adjusted to 8.3 
Blocking buffer 1x TBST 5% BSA (bovine serum albumin) 
1X TBST 
20 mM Tris base 
150 mM NaCl 
0.1% Tween 20 
Substrat buffer for alkaline phosphatase 
5mM MgCl2  
100mM Tris-HCl, pH 9.5 
100 mM NaCl  
BCIP 
20mg mL
-1
 5-bromo-4-chloro-3-indolyl phosphate 
in 100% DMF 
NBT 
50mg mL
-1
 p-nitroblue tetrazolium chloride in 
70% DMF 
5.7.8 Protein quantification 
Table 19: Buffers and solutions used for the protein quantification 
Buffer Components and preparation 
BCA Protein Assay Kit  PierceTM 
BSA stock solution  10mg mL
-1
 bovine serum albumin 
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5.7.9 Activity assays 
Table 20: Buffers and solutions used for the activity assays. 
Buffer Components and preparation 
Arginine kinase assay 
100 mM Tris-HCl buffer pH 7.5 
1mM phosphoenolpyruvate 
5mM MgCl2 
50mM KCl 
0.15 mM NADH 
4U of pyruvate kinase 
8U of lactate dehydrogenase 
2.5 mm ATP 
10 mM L-arginine 
enzyme solution 
Shikimate kinase assay 
100 mM Tris–HCl buffer pH 7.5 
1 mM phosphoenolpyruvate 
5 mM MgCl2 
50 mM KCl 
0.15 mM NADH 
4U of pyruvate kinase 
8U of lactate dehydrogenase 
 2.5 mM ATP 
1.6 mM of Shikimic acid 
enzyme solution  
Argininosuccinate lyase assay 
50 mM KPP buffer pH 7.5  
1 mM of potassium  
Argininesuccinate enzyme solution 
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5.7.10 TLC Visualization Reagents 
Table 21.: Reagents used for TLC detection 
Solution Components and preparation 
Cer-reagent 
2.5% (w/v) H3[P(Mo3O10)
4
] x H2O 
1% (w/v) Cer(SO4)2 
8% (v/v) conc. H2SO4 
Filled with dest. water and filtered 
Vanilin-reagent 
0.5g vanillin in 100ml sulfuric acid/ethanol 
(40:10). 
Running solution 
DCM/Acetone/Acetic acid 
60/15/1 
 
5.8 Equipment 
Table 22: Used equipment. 
Equipment Name Producer 
Agarose electrophoresis  
Mini-Sub Cell  Bio-Rad (Munich, Germany)  
GT Compact XS/S 
Biometra GmbH (Göttingen, 
Germany) 
Balances  
PCB350-3 
PCB2500-2 
Kern & Sohn GmbH (Belingen, 
Germany  
Explorer E14130 Ohaus (Parsippany, USA) 
MC1 Analytic AC 120S Sartorius (Göttingen, Germany) 
Centrifuges Biofuge  
Biofuge pico  
Thermo Fisher Scientific 
(Waltham, USA) 
Biofuge 400R  
Thermo Fisher Scientific 
(Waltham, USA) 
Multifuge 3S-R 
Thermo Fisher Scientific 
(Waltham, USA) 
Fresco 17 
Thermo Fisher Scientific 
(Waltham, USA) 
Sprout-Minizentrifuge 
Biozym Scientific (Oldendorf, 
Germany) 
Cell lysis Sonoplus HD/UW 2070  Bandelin (Berlin, Germany)  
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Equipped with: 
Ultrasonic horn MS72 Ultrasonic 
horn KE76  
Hielscher sonicator UP200St. 
Equipped with: 
Glass beads (Ø 0.25-0.5 µm) 
Hielscher ( Berlin, Germany) 
Cleanbench HeraSafe KS15  
Thermo Fisher Scientific 
(Waltham, USA) 
FPLC  ÄKTApurifier  
GE Healthcare (Buckinghamshire, 
United Kingdom) 
Gas chromatography 
GC-2010(plus) incl. AOC-20i-s  
Shimadzu (Duisburg, Germany) 
 
GCMS-QP2010  Shimadzu (Duisburg, Germany) 
Heating-/stirring plate RCT basic  
IKA Labortechnik (Staufen, 
Germany 
Homogenization FastPrep-24 
MP Biomedicals, Inc. (Eschwege, 
Germany) 
HPLC 
LaChrom L7100   
Equipped with L7100 pump, 
L7420 UV-Detector, L7200  
Merck Hitachi (Darmstadt, 
Germany) 
 
Autosampler, D7000 Interface  
Merck Hitachi (Darmstadt, 
Germany) 
Incubation  
 
Incucell  
MMM Medcenter Einrichtungen 
GmbH(Gräfelfing, Germany)  
Multitron Standard 
Infors AG (Bottmingen, 
Switzerland)  
Minitron 
Infors AG (Bottmingen, 
Switzerland) pH 
Lyophilisator Alpha 1-2, Christ GmbH (Osterode am Harz) 
pH-meter  PH211 
Hanna Instruments (Vöhringen, 
Germany) 
Photometer  
Jasco V-550 with PSC-498T 
Temperature controller  
Jasco Analytical Instruments 
(Easton USA) 
NanoDropTM 1000 UV  Peqlab (Erlangen, Germany) 
Mini-1240 Shimadzu (Duisburg, Germany) 
Power supply for electrophoresis  
EPS EV231  
Standard Power Pack 25  
Consort (Turnhout, Belgium)  
Biometra (Göttingen, Germany) 
Protein electrophoresis Minigel-Twin Biometra (Göttingen, Germany) 
Sterilization V-120 autoclave Systec (Bergheim-Glessen, 
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Germany) 
Laboklav ECO 
SHP Steriltechnik AG (Detzel, 
Germany) 
Dry-Line oven 
VWR International (Darmstadt, 
Germany) 
TLC  
Färbekasten nach Hellendahl 
(85x35x95 mm) 
Roth(Karlsruhe,Germany) 
Thermocycler Thermocycler Analytic Jena (Jena, Germany) 
Thermoshaker Thermomixer comfort Eppendorf (Hamburg, Germany) 
UV table Benchtop UV Transiluminator UVP (Upland, USA) 
Vortex Vortex Genie 2 
Scientific Industries (Bohemia, 
USA) 
96-well plate reader Infinite® M200PRO 
Tecan Trading AG (Männedorf, 
Switzerland) 
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6 Methods 
6.1 Microbiological methods 
6.1.1 Strain maintenance  
Transformants and strains were kept on agar plates (LB for E. coli and YPD for P. pastoris ) 
and stored at 4°C. For more extended storage at 4°C, fresh plates were prepared every 6–8 
weeks. For long-term storage, glycerol stocks were made for each strain/transformant. Here, 1 
mL overnight culture was mixed 1:1 with a 60% glycerol solution. The vials with the mixture 
were stored at -80°C. 
6.1.2 Overnight cultures 
For the preparation of overnight cultures, 5 of medium containing an appropriate selection of 
marker(s) (LB for E. coli and YPD for P. pastoris) were inoculated with single colonies 
picked from agar plates. These cultures of E.coli and P. pastoris were grown overnight at 
37°C, 200 rpm and 30°C, 250 rpm respectively for 24 hours. 
6.1.3 Preparation of competent cells 
6.1.3.1 Preparation of chemically competent E. coli cells 
Rubidium chloride method was used for the preparation of chemically competent E. coli cells. 
LB medium (100 mL) was inoculated with an overnight culture and incubated at 37°C and 
200 rpm until the culture reached OD600=0.3-0.4. Afterwards, the cells were harvested, chilled 
on ice for 15 min, and centrifuged at 4°C for 25 min at 4000 x g. The pellet created in the 
process was then resuspended in 20 mL ice-cold RF1 buffer, incubated at 4°C for 15 min and 
centrifugated at 4°C for 25 min at 4000 x g. The pellet was resuspended again, but this time in 
4 mL RF2 buffer, incubated at 4°C for 15 min and distributed in 50 μL aliquots. These 
aliquots were immediately frozen in liquid nitrogen and stored at -80°C. 
6.1.3.2 Preparation of electrocompetent P. pastoris cells 
YPD medium (5 mL) was inoculated with a single colony of Pichia pastoris strain and grown 
overnight at 30°C in an incubator with shaking (200 rpm). YPD medium (500 mL) was 
inoculated with 0.5 mL of overnight culture and grown overnight at 30°C and 200 rpm to an 
OD600=1.3-1.5. Cells were then harvested and centrifuged at 1500x g for 5 minutes at 4°C. 
Pellet was resuspended with 500 mL of ice-cold (0°C), sterile water. The cells were 
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centrifuged again at 1500x g for 5 minutes at 4°C; then the pellet was resuspended with 250 
mL of ice-cold (0°C), sterile water. Cells were centrifuged for the third time at 1500x g for 5 
minutes at 4°C, and the pellet was resuspended with 20 mL of ice-cold (0°C), 1M sorbitol. 
Afterwards, the cells were centrifuged at 1500x g for 5 minutes at 4°C, and the pellet was 
resuspended in 1 mL of ice-cold (0°C), 2M sorbitol for a final volume of approximately 1.5 
mL and distributed in 100 μL aliquots. These aliquots were immediately frozen in liquid 
nitrogen and stored at -80°C. 
6.1.4 Transformation 
6.1.4.1 Transformation of chemically competent E. coli cells 
To a 50 μL aliquot of E. coli cells, 1-10 μL of DNA solution was added, and the mixture was 
incubated for 30 min on ice. The cells were permeabilised by heat shock (30 sec at 42°C) and 
chilled on ice for 5-10 min. Next, 300 μL of LB-SOC medium was added to the cells and 
incubated for 1-3 hours at 37°C with 200rpm shaking. Different volumes of the culture were 
plated on agar, supplemented with an adequate antibiotic and incubated overnight at 37°C. 
6.1.4.2 Transformation of electrocompetent P. pastoris cells 
To a 100 µL aliquot of P. pastoris cells, 10µL of DNA (5-10µg) solution with low salt 
concentration was added. The mixture was gently mixed and immediately transferred to an 
ice-cold electroporation cuvette and incubated on ice for 5 minutes. Electroporation was 
performed for 5 ms at 1500 mV in a MicroPulser (BioRad). Right after the electronic impulse, 
1 mL of ice-cold 1M sorbitol was added to the cells. The cells were transferred to a 15 mL 
sterile tube and incubated for 2 hours without shaking at 30°C. 1 mL of YPD medium was 
added to the cells and incubated for 3 hours at 30°C and 200 rpm. Afterwards, 200 µL of the 
culture were platted on YPDS agar, supplemented with the zeocin (25 μg mL-1) and incubated 
for three days at 30°C until colonies appeared. 
6.2 Cultivation and Protein Expression 
6.2.1 Arginine kinase 
Selected E. coli transformants were used for expression tests, in which different media, 
induction times and temperatures were optimised. The selected conditions were later used for 
the overexpression of ArgK in E. coli BL21 (DE3). For overexpression arginine kinase, 50 
mL of Terrific Broth (TB) medium supplemented with kanamycin (50 µg mL-1) was 
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inoculated with 500 µL of the corresponding overnight culture. 50 mL and cultivated at 37ºC 
and 150 rpm in a 250 mL Erlenmeyer flask with baffles. When the pre-culture reached the 
mid-log phase, the main culture was started. Hence, 400 mL of fresh TB medium in a 2L 
Erlenmeyer flask was inoculated with 20 mL of the E. coli pre-culture. After the culture 
reached an OD600 of 1.3 (optical density), protein expression was induced with 1mm of 
isopropyl-b-d-thiogalactopyranoside (IPTG). The main culture was shaken at 110rpm for 20h 
at 25ºC. The cells were harvested at 4500g for 30 min at 4°C. If not used directly, the cell 
pellets were stored at -20°C until further usage. 
6.2.2 Shikimate kinase 
Selected E. coli transformants were used for expression tests, in which different media and 
temperatures were optimised. The selected conditions were later used for the overexpression 
of AroL in E. coli BL21 (DE3). For overexpression shikimate kinase 50 mL of Terrific Broth 
(TB) medium supplemented with kanamycin (50 µg mL-1) was inoculated with 500 µL of the 
corresponding overnight culture and cultivated at 37ºC and 150 rpm in a 250 mL Erlenmeyer 
flask with baffles. When the pre-culture reached the mid-log phase, the main culture was 
started. Hence, 400 mL of fresh TB medium in a 2L Erlenmeyer flask was inoculated with 20 
mL of the E. coli pre-culture. After the culture reached an OD600 of 1.3 (optical density), 
protein expression was induced with 1mM of isopropyl-β-D-thiogalactopyranoside (IPTG). 
The main culture was shaken at 110rpm for 20h at 25ºC. The cells were harvested at 4500g 
for 30 min at 4°C. If not used directly, the cell pellets were stored at -20°C until further usage. 
6.2.3 Argininosuccinate lyase 
Selected E. coli transformants were used for expression tests, in which different media, 
induction times and temperatures were optimised. The selected conditions were later used for 
the overexpression of aroL in E. coli BL21 (DE3). For overexpression argininosuccinate 
lyase, 50 mL of Terrific Broth (TB) medium supplemented with kanamycin (50 µg mL-1) was 
inoculated with 500 µL of the corresponding overnight culture and cultivated at 37ºC and 150 
rpm in a 250 mL Erlenmeyer flask with baffles. When the pre-culture reached the mid-log 
phase, the main culture was started. Hence, 400 mL of fresh TB medium in a 2 L Erlenmeyer 
flask was inoculated with 20 mL of the E. coli pre-culture. After the culture reached an 
OD600 of 1.3 (optical density), protein expression was induced with 1mM of isopropyl-β-D-
thiogalactopyranoside (IPTG). The main culture was shaken at 110rpm for 20h at 25ºC. The 
cells were harvested at 4500g for 30 min at 4°C. If not used directly, the cell pellets were 
stored at -20°C until further usage. 
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6.2.4 Monooxygenase P450_OleP 
The pET28a(+) plasmid encoding the gene CYP107D1 was transformed via heat shock into 
the E. coli strain C43 (DE3) and co-transformed with the vector pACYCDuet, which 
contained the redox partner genes (putidaredoxin (CamA) and putidaredoxin reductase 
(CamB) from Pseudomonas putida). Positive transformants were used for expression tests, 
where different media, induction time, inducer concentrations and temperature were tested. 
The selected condition was later used for over-expression of CYP107D1 and redox partner 
genes. The transformants were grown overnight in 5 mL Lysogeny Broth medium (LB) with 
50μg mL-1 kanamycin and 34μg mL-1 chloramphenicol at 37°C and 180rpm. The following 
morning 50mL Terrific Broth medium (TB) supplemented with chloramphenicol and 
kanamycin (35μg mL-1  and 50μg mL-1, respectively) was inoculated with 500 μL of an 
overnight culture as a pre-culture in a 250mL shake flask. At mid-log phase, 400 mL of fresh 
TB medium in 2 L Erlenmeyer flask was inoculated with 20 mL of an E. coli pre-culture. 
After the absorbance reached an OD=1.3 at 600 nm, protein expression was induced with 
1mM of isopropyl-β-D-thiogalactopyranoside (IPTG) and cells were supplemented with 5-
aminolevulinic acid (84 µg mL-1) as a precursor for the heme synthesis in E. coli. The cultures 
were shaken at 30°C at 110rpm for 20h and cells were harvested by centrifugation at (13300g 
for 30min at 4°C). Cells were washed once with ice-cold 50mM potassium phosphate buffer 
at pH7.4 and cell pellets were frozen at -20°C (Bracco et al. 2013b).  
6.2.5 Monooxygenase P450_FG0067 
6.2.5.1 Monooxygenase P450_FG0067 E. coli expression  
The gene encoding P450_FG067 in pET24a(+) plasmid was transformed with heat shock 
method into the E. coli strain C43 (DE3). The transformants were grown overnight in 5 mL 
Lysogenic Broth medium (LB) with 50μg mL-1 kanamycin at 37°C and 180 rpm. The 
following morning 50 mL of Terrific Broth medium (TB) supplemented with kanamycin 
(50μg mL-1) was inoculated with 500 μL of an overnight culture as a pre-culture in a 250 mL 
shake flask. At mid-log phase, 400 mL of fresh TB medium in a 2 L Erlenmeyer flask was 
inoculated with 20 mL of an E. coli pre-culture. After the absorbance reached OD=1.3 at 600 
nm, protein expression was induced with 1mM of isopropyl-β-D-thiogalactopyranoside 
(IPTG) and cells were supplemented with 5-aminolevulinic acid (84 µg mL-1) as a precursor 
for the heme synthesis in E. coli. The cultures were shaken at 30°C, and 110 rpm for 20 h and 
cells were harvested by centrifugation at 13300 g for 30 min at 4°C. Cells were washed once 
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with ice-cold 50mM potassium phosphate buffer at pH 7.4 and cell pellets were frozen at –
20°C. 
6.2.5.2 Monooxygenase P450_FG0067 P. pastoris expression  
The Pichia pastoris strain BG10 was transformed by electroporation. The vector 
pPICZ(A)_P450-FG067 was linearised with the SacI restriction enzyme,  purified via the 
QIAquick PCR Purification Kit (Qiagen, Germany) and transformed into P. pastoris BG10 
using an electroporation method from the expression kit manual (Invitrogen). The 
recombinant strains were selected with the use of Zeocin, and the insertion of the fusion gene 
into the genomic DNA of the recombinants was confirmed by PCR method described in the 
expression kit manual (Invitrogen). Recombinant P. pastoris BG10 were cultivated in 400 
mL. BMGY growth medium containing yeast extract (1%), peptone (2%), Yeast Nitrogen 
Base (1,34% (w/o AA)), biotin (4µg mL-1) and glycerol (1%) in 100mM Potassium phosphate 
pH 6.0 was inoculated with single colonies of P. pastoris (50 mL). The cells were cultured at 
30°C for 24 h. The cells were then collected by centrifugation for 10 min at 3000 g, 4°C and 
resuspended to an approximate OD600 of 2 in 400 mL of BMMY medium supplemented with 
0.5 μM hemin chloride and zeocin (100 µg mL-1). Cells were grown at 30°C with 110 rpm 
shaking and induced for 24 h by adding methanol (0.5%) every 24 h. After 96 h, the cells 
were harvested by centrifugation at 5000 g for 25 min at 4°C and washed once with an ice-
cold 50 mM sodium phosphate buffer at pH 7.5. The P. pastoris cell pellets containing the 
overexpressed enzyme (rec. P450_FG067) were frozen at –20°C.  
6.2.6 Cell disruption 
For cell disruption of E. coli containing overexpressed arginine kinase, shikimate kinase and 
argininosuccinate lyase, frozen cells were adjusted to an OD600 of 40 in a buffer (50mM 
TrisHCl, pH7.5 for arginine kinase, shikimate kinase and potassium phosphate buffer 50mM, 
pH 7.5 for argininosuccinate lyase), mixed with glass beads (Ø 0.25-0.5 µm) at an 
approximate ratio of 1:1 and 10. The suspension was sonicated at 0°C for 20 min and interval 
pulsed at alternating cycles (Hielscher sonicator UP200St: 50% power and 50% pulse). 
Insoluble cell debris was removed by centrifugation at 13300g for 30 min at 4°C. The 
supernatant, which contained the soluble protein fraction, was immediately used for activity 
determination. A 50μl samples of whole-cell homogenate, supernatant and a cell pellet were 
mixed with 2× SDS sample buffer and thermally denaturated for 8 min at 95°C. The 
supernatant, which contained the soluble protein fraction, was immediately used for activity 
determination. For cell disruption of E. coli containing P450_OleP/putidaredoxin 
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(CamA)/putidaredoxin reductase (CamB) and P450_FG067, frozen cells were adjusted to an 
OD600 of 40 in potassium phosphate buffer (KPp: 50mM, pH7.4), the suspension was 
sonicated at 0°C for 20 min and pulsed intervally at alternating cycles (Hielscher sonicator 
UP200St: 50% power and 50% pulse). Insoluble cell debris was removed by centrifugation at 
13300g for 30 min at 4°C. The supernatant, which contained the soluble protein fraction, was 
immediately used for activity determination. 
For P. pastoris cell disruption containing P450_FG067, frozen cells were adjusted to an 
OD600 of 40 in potassium phosphate buffer (50 mM, pH7.5), mixed with glass beads (Ø 0.25-
0.5 µm) at an approximate ratio of 1:1 and 10 U of lyticase was added. After incubation for 30 
min on ice, the cells were disintegrated mechanically by a cell disruptor (Retsch Mixer Mill 
MM 200) 200) for cycles for 3 min full-speed vortexing followed by 1min cooling on ice. The 
samples were cooled on ice and insoluble cell debris was removed by centrifugation (13300 g, 
30 min, 4°C). A 50μl samples of whole-cell homogenate, supernatant and a cell pellet were 
mixed with 2× SDS sample buffer and thermally denaturated for 8min at 95°C. The 
supernatant, which contained the soluble protein fraction, was immediately used for activity 
determination.  
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6.3 Molecular biology methods 
6.3.1 Plasmid isolation 
Plasmids were isolated by the usage of the innuPREP Plasmid Mini Kit (Analytik Jena). All 
steps were performed as described in the manufacturer’s manual. The elution of plasmid DNA 
was conducted with 50 μL of elution buffer previously warmed up to 95°C and cooled down 
to 70°C. 
6.3.2 PCR methods 
6.3.2.1 Subcloning pUC_FG067-pET24FG-067 
Table 23: Master Mix  
Component 5 samples [µL] 
10X Reaction Buffer + MgCl2 50 
dNTPs 5 
FW-E15 primer (10 pmol/μl) 25 
RV-E16 primer (10 pmol/μl) 25 
MilliQ water 140 
Template DNA 10 
Phusion DNA Polymerase (0.05 U/μl ) 2,5 
 
Table 24: Temperature program used for the subcloning of p450-FG067. 
Step Temperature Time Cycle 
Initial denaturation 98°C 1 min. 
 
Denaturation 98°C 10 sec. 
30x Annealing 53°C 30 sec. 
Extension 72°C 1 min 30 sec. 
Final Extension 72°C 10 min. 1x 
 
4°C   
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6.3.3 Colony PCR 
In general, colony PCR was applied to identify clones harbouring the freshly introduced 
plasmid. 
6.3.3.1 Verification of the plasmid integration via colony PCR in P. pastoris 
This reaction was used as a control of the ligation processes to test P. pastoris clones for 
insertion of pPICZα-P450-FG067 by PCR. Briefly, the cells are lysed by a combined enzyme, 
freezing, and heating treatment. The genomic DNA was used directly as a PCR template. At 
least 20 colonies were analysed each time. 
 
Table 25: Master Mix P. pastoris colony PCR. 
Component 5 samples [µL] 
10X Reaction Buffer 5 
25 mM MgCl2 5 
5'AOX1 primer (10 pmol/μl) 1 
3'AOX1 primer (10 pmol/μl) 1 
MilliQ water 28 
Cell lysate 5 
Taq polymerase (0.16 U/μl ) 5 
 
Table 26: Temperature program fort the colony PCR of P. pastoris 
Step Temperature Time Cycle 
Denaturation 95°C 1 minute 
30x Annealing 54°C 1 minute 
Extension 72°C 1 minute 
Final Extension 72°C 7 minutes 1x 
The reaction products were afterwards analysed by electrophoresis using 1% agarose.  
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6.3.3.2 Digestion of pPICZα-P450-FG067 
The construct pPICZα-P450-FG067 was linearized by digestion with Sac I. 
DNA was digested overnight at 37°C.  
Table 27: Digestion mixture composition 
 
Component µL 
10 x digestion buffer 10 
40 μL DNA 40 
10 μL Sac I 10 
MilliQ water 40 
 
This reaction was used for linearization of DNA to stimulate recombination when the plasmid 
is transformed into P. pastoris. 
6.4 Quantification of DNA 
6.4.1 Nano drop 
Determination of DNA concentrations was achieved by the usage of UV-Vis photometer 
NanoDrop. The device measures absorbance at a wavelength of λ=260 nm. Additionally, 
other important wavelengths are measured to assure the purity of the DNA sample. 
6.5 Agarose gel electrophoresis 
For separation of DNA fragments or plasmids by size, agarose gel electrophoresis was 
applied. The agarose gel was prepared with TAE buffer, which was heated until boiling in the 
microwave oven to solve the appropriate amount of agarose. 5 µL of Roti-GelStain (Carl 
Roth) were added per 100 mL agarose solution for later visualisation of DNA. The gel was 
casted and left for cooling. Samples were prepared by mixing with 6x loading dye (1:6). After 
applying 6 µL of each sample and 5 µL DNA ladder (1kbp DNA ladder, Carl Roth), the gel 
was run at 110 V for 25 min. The final result was investigated after illumination on a UV 
table. 
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6.6 Biochemical methods 
6.6.1 Protein purification 
6.6.1.1 Hand columns 
In general, approximately the same protocol was used for all proteins if hand columns were 
used for purification (arginine kinase, shikimate kinase, ASL). When the cell pellet was stored 
at -20°C, then it was thawed slowly on ice and washed two times with equilibration buffer. 
After cell lysis in equilibration buffer, by sonication, the crude cell lysate was separated by 
centrifugation at 10000g for 1h at 4°C. After filtering the supernatant with a 0.45 µm filter, 
the His-tagged enzyme was purified on a Ni-NTA hand column (Roti®garose-His/Ni Beads, 
Carl Roth GmbH & Co. KG, Germany). First, the column was washed and preequilibrated 
with five column volumes (5 CV) of equilibration buffer, followed by loading of the filtered 
supernatant. Secondly, after washing the column with 2 CV of wash buffer, the protein was 
eluted. The elution was obtained with 2 CV of elution buffer. Finally, the eluted protein 
sample was desalted and stored in storage buffer or used immediately. 
6.6.1.2 ÄKTApurifier 
To purify the recombinant P450 Monooxygenase OleP and P450 Monooxygenase FG0067 by 
IMAC (immobilised metal ion chromatography) with FPLC ÄKTA-purifier. In this research 
1mL HiTrap IMAC HP prepacked columns with sepharose matrix functionalized with 
chelating groups charged with Ni
2+
 was used. The system was equilibrated with sodium 
phosphate buffer (pH 7.4) and supplemented with 500 mM NaCl. To prevent non-specific 
binding of protein, 30mM imidazole was included both in-sample and in binding buffer. In 
the purification procedure performed in native conditions. After equilibrating the whole 
system with the used buffer, the column was washed with 5 CV equilibration buffer. 
Afterwards, the protein was loaded onto the column and elution was accomplished by a linear 
gradient over 5 CV changing gradually from the equilibration buffer to the elution buffer. All 
the chromatographic steps were carried out at 1 mL min
-1
 flow rate. 
6.6.1.3 Desalting 
All obtained elution fractions from protein purification were desalted using PD-10 columns 
(GE Healthcare, Freiburg, Germany). Desalting was performed as suggested by the 
manufacturer. The buffer used for elution from the column was different for all proteins. In 
most cases, the storage buffer was used. 
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6.6.2 Protein quantification 
6.6.2.1 BCA assay 
Protein concentrations of samples was determined using the PierceTM BCA Assay Kit 
(Thermo Fisher Scientific, Waltham, USA). The assay performed according to the 
manufacturer’s instructions for the 96-well plate format. After incubation for at least, 30 min 
at 37°C, the absorbance of all samples at λ=562nm was determined. BSA standard solutions 
were always prepared fresh with the same buffer that the samples contained.was  
6.6.3 SDS-PAGE 
According to general procedure, stacking and resolving gel were made and poured into the gel 
form. Soluble and insoluble fractions were always analysed separately. Soluble fraction: 10 
μL samples were mixed with 5 μL loading buffer and heated at 95°C for 10 min. Insoluble 
fraction: The pellet was resuspended with 500 μL of 0.1% Triton X-100 solution and 
incubated at 37°C for 10 min. It was washed twice with 500 μL of 50 mM sodium phosphate 
buffer (pH 7.4) and resuspended in 20 μL loading buffer. This mixture was heated at 95°C for 
10 min.  The gels ran at 200 V until the bromophenol blue band reached the front of the gel. 
The protein bands were visualised by Coomassie Brilliant Blue staining. Standards for protein 
size were present in all gels. 
6.6.4 Coomassie staining 
For visualisation of the protein bands, SDS gels were stained by incubation in staining 
solution overnight (Coomassie staining). The next day the background of the gels was 
destained with destaining solution, which was exchanged at least twice. The gels were 
incubated in the destaining solution until clear protein bands, and only a little or no 
background colour could be observed. 
6.6.5 Heme Staining 
To facilitate in-gel detection of free or P450 associated heme, the method of Thomas et al. 
was utilized
 
(Thomas et al. 1976). Briefly, 9% resolving gels were preelectrophoresed at 10°C 
overnight at low voltage to remove excess ammonium persulfate. Samples were boiled for 5 
min in buffer containing 7% SDS prior to loading. The use of DTT or other thiol-containing 
agents was explicitly avoided due to their propensity to react with heme and potentially 
interfere with the heme peroxidase activity necessary for staining. Electrophoresis was carried 
out in fresh buffer over the course of 2-3 h at 10ºC. To stain gels for heme detection, a 1.5 mg 
mL
-1
 solution of TMBZ was freshly prepared in methanol. After the TMBZ dissolved fully, 3 
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parts of the resulting solution were mixed with 7 parts of 250 mM sodium acetate buffer (pH 
5.0). Gels were immersed in this mixture for 1-2 h in the dark before the addition of hydrogen 
peroxide to a final concentration of 30 mM. Over the next 30 min, light blue bands emerged, 
indicating the presence of heme. Photographs were taken immediately after the gels were 
developed as the staining intensity eventually diminishes due to light sensitivity. Shortterm 
storage of stained gels could be achieved in 1:2:17 glacial acetic acid/2-propanol/water. 
Staining of gels for protein content was carried out with Coomassie R250 dye using standard 
procedures. Protein samples for Coomassie gels were treated identically to those for TMBZ 
staining so that results from the different staining techniques could be compared directly. 
6.6.6 Western blot 
Proteins were transferred from the respective SDS gel to nitrocellulose membranes by the wet 
blotting procedure. Therefore, for every gel to be blotted, two stacks of three blotting papers, 
cut to approximate gel size, were soaked in the blotting buffer. A nitrocellulose membrane 
was cut to the gel size and soaked in the blotting buffer for a short time. At the same time, the 
SDS gel had been incubated in blotting buffer before it was transferred onto one blotting 
paper stack in a wet blotting chamber. The equilibrated nitrocellulose membrane and the 
second blotting paper stack were piled on top, and potential air bubbles were removed by 
applying pressure gently onto the stack from the middle towards the border. Electroblotting 
was performed by administering 100 mA/blotted gel at 120V and 50W for 1h, thus pulling the 
negatively charged proteins from the SDS gel onto the nitrocellulose membrane towards the 
positively charged electrode of the blotting chamber. In order to prevent unspecific antibody 
binding during the following incubation steps, membranes were blocked in a blocking 
solution. The incubation was carried out under gentle agitation for 30 min at RT. For specific 
labelling of a given protein, the respective primary antibody (Anti-His6) was diluted 
(1:10000) in a washing solution. Samples were then incubated at RT for 1h or at 4°C 
overnight on a rocker. After that, membranes were washed three times for 10 minutes in a 
washing solution to eliminate unbound antibody residues and subsequently incubated with the 
anti-mouse AP, a secondary antibody diluted 1:10000 in a washing solution. After incubation 
at RT for 1h blots were again rinsed several times in a washing solution for residual antibody 
removal. The secondary antibodies were visualised for alkaline phosphatase. Alkaline Tris-
buffer containing BCIP/NBT was used, and the colour reaction was stopped with ddH2O. 
Methods 
122 
6.7 Activity determination 
6.7.1 Arginine kinase Assay 
This assay, for the quantification of arginine kinase in liquid medium, is based on the 
transformation of arginine and ATP into phospho-arginine and ADP by the enzyme. ADP is 
measured by two coupling reactions involving pyruvate kinase (EC 2.7.1.40) and lactate 
dehydrogenase (EC 1.1.1.27) with measurement of NADH consumption at 340 nm for 60 
seconds. The amount of reagents required for the assay of arginine kinase is summarized in 
Table 28. 
Table 28: Reagents for enzymatic assay of arginine kinase. A reaction cocktail was prepared by pipetting the 
following reagents into a suitable containers: 
 
The reaction cocktail was prepared by pipetting (in µliters) reagents (Tab. 28) into a suitable 
cuvettes (Tab. 29). 
  
Components Final concentration Reagents 
Tris-HCl pH 7,5 100mM 
50mM 
5mM 
A KCl 
MgCl2 
ATP 250mM 
B PEP 100mM 
NADH 10mM 
LDH 82U mL
-1 
C 
Pyruvat-Kinase 40U mL
-1
 
L-Arginine 1M D 
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Table 29: Procedure for enzymatic assay of arginine kinase 
The reaction cocktail was prepared by pipetting (in µlliters) the following reagents into a suitable cuvettes. 
* blank: denaturized enzyme by heating at 95°C for 10 minutes 
Decrease of absorbance at 340 nm is monitored for 60 sec. Arginine kinase activity can be 
calculated as: 
          
 
  
  
   
     
   
        
     
   
          
      
 
df = Dilution factor 
ε =6.22- Millimolar extinction coefficient of ß-NADH at 340 nm  
0.05 = Volume (in milliliter) of enzyme used   
Components Reagents μl 
Tris-HCl pH 7,5 
A 740 KCl 
MgCl2 
ATP 
B 100 PEP 
NADH 
LDH 
C 100 
Pyruvat-Kinase 
L-Arginine D 10 
Arginine kinase E 50 
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6.7.2 Shikimate kinase Assay 
The enzymatic activity of Shikimate kinase was evaluated by using a double coupled assay 
involving pyruvate kinase (EC 2.7.1.40) and lactate dehydrogenase (EC 1.1.1.27). During the 
assay, the ADP generated by Shikimate kinase led to the oxidation of NADH to NAD+. All 
assays were conducted by measuring the decrease in absorbance at 340 nm. The amount of 
reagents required for the assay of shikimate kinase is summarised in Table 30. 
Table 30: Reagents for enzymatic assay of shikimete kinase. A reaction cocktail was prepared by pipetting the 
following reagents into a suitable containers: 
  
Components Final concentration Reagents 
Tris-HCl pH 7,5 100mM 
A KCl 50mM 
MgCl2 5mM 
ATP 2,5mM 
B PEP 1mM 
NADH 0,1- 0,15mM 
LDH 8U 
C 
Pyruvat-Kinase 4U 
Shikimic acid 1,6mM D 
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Table 31: Procedure for enzymatic assay of shikimate kinase. 
The reaction cocktail was prepared by pipetting (in µlliters) the following reagents into a suitable cuvettes. 
* blank: denaturized enzyme by heating at 95°C for 10 minutes 
          
 
  
  
   
     
   
        
     
   
          
      
 
df = Dilution factor 
ε =6.22- Millimolar extinction coefficient of ß-NADH at 340 nm  
0.05 = Volume (in milliliter) of enzyme used   
Components Reagents μl 
Tris-HCl pH 7,5 
A 740 KCl 
MgCl2 
ATP 
B 100 
PEP 
NADH 
LDH 
C 100 
Pyruvat-Kinase 
Shikimic acid D 10 
Shikimate kinase E 50 
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6.7.3 Argininosuccinate lyase Assay 
The enzymatic activity of argininosuccinate lyase was assayed at room temperature by 
recording at 240nm formation of fumarate during the reaction. The amount of reagents 
required for the assay in the cuvette is summarised in Table 13. 
Table 32: Procedure for enzymatic assay of argininosuccinate lyase. The reaction cocktail was prepared by 
pipetting (in µlliters) the following reagents into a suitable cuvette. 
Increase of absorbance at 240 nm is monitored for 60 sec. Argininosuccinate lyase activity 
can be calculated as: 
          
 
  
  
   
     
   
        
     
   
          
      
 
 
df = Dilution factor 
ε = 2.42- Millimolar extinction coefficient of fumarate at 240 nm  
0.05 = Volume (in milliliter) of enzyme used 
6.7.4 Determination of P450 concentration 
The finally obtained P450 concentration was determined using the CO assay as described by 
Guengerich et al. 2009 (Guengerich et al. 2009). Samples from fermentation and 
biotransformations were stored in the form of frozen cell pellet until the analysis. The final 
P450 concentration was obtained and then determined using the CO assay as described by 
Omura et al. 1964. The 2 mL sample was mixed with 2μM safranin T as a redox indicator, 
followed by the addition of one spatula tip of sodium dithionite. By inverting the tube slowly, 
the solution was mixed, and 1 mL each was transferred in a new cuvette. Approximately one 
bubble min-1 CO-gas is applied for 1 min in one cuvette. A different sample is measured as 
blank. Then, a spectrum is recorded between λ=400 nm and  λ=500 nm. With this difference 
spectrum, the concentration of cytochrome P450 enzymes can be determined (Table. 14). 
With this difference spectrum, the concentration of cytochrome P450 enzymes can be 
determined (Equation 2). 
  
             
               
 
Components Reagents μl 
50mM Potassium Phosphate Buffer 50mM final concentration 950 
Argininosuccinate 10mM standard concentration 100 
ASL enzyme solution 50 
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Equation 2: Equation for calculating the concentration of correctly folded Cytochrome P450 enzyme, from 
values determined by the recorded difference spectrum. 
Table 33: Settings used for the recording of CO difference spectra using the Jasco device. 
Parameter  Setting  
Wavelength 500 - 400 nm  
Photometric mode  Abs  
Response  medium  
UV/Vis bandwidth  0.2 nm  
Scan speed  200 nm/min  
Delta interval 1nm 
Scan mode  Continuous  
Number of cycles  1 
Vertical scale  Auto 1 - 0 
 
6.7.5 Cytochrome c and DCPIP assay 
Cytochrome c reductase activity of the fractions was assayed by using cytochrome c reductase 
(NADPH) assay kit (Sigma Aldrich). The reaction was initiated by addition of NADPH, and 
the reduction of cytochrome c is monitored by the increase of absorbance at 550 nm for 7 min 
with the kinetic program. With DCPIP, assays were performed in 20 mM Tris-HCl buffer 7.4 
at 25°C in the presence of 70 μM DCPIP. Reduction of the DCPIP colour indicator (an 
artificial one electron acceptor) was quantified by rates of decrease in absorbance at 600 nm 
over 10 min (Gray et al. 2010).  
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6.8 Biocatalysis 
6.8.1 Whole-cell biocatalysis with the OleP 
With E. coli C43 (DE3) cells harbouring the pET-28a-oleP and pACYC-pdR/pdX coding the 
CYP107D1 and reductase/ferredoxin system PdR/PdX, whole-cell biocatalysis according to 
Glazyrina et al. was performed (Glazyrina et al. 2010). Cells were resuspended in resting cell 
medium (200mM KH2PO4/K2HPO4, 20mM NaCl, 1% (w/v) glucose, 0.4% (w/v) glycerol, pH 
7.4) and adjusted to a cell dry weight of 6.6 g·L-1. The substrate was added to a final 
concentration of 2mg·mL-1 from a 100mg·mL-1 stock solution in DMSO. Reactions were 
incubated at 28°C with shaking at 160rpm. Samples (1mL) were taken over a period of 24 h 
and centrifuged (13300g, 5min) to remove cells. The supernatants were used for 
quantification of bile acids.  
6.8.2 Whole-cell biocatalysis with the P450_FG67 
One gram of P. pastoris cell pellet was suspended in 10 mL potassium phosphate buffer (50 
mM, pH 7.4). Preparative-scale bioconversions were carried out in 2 mL potassium phosphate 
buffer (50 mM, pH 7.4) using resting whole cells of P. pastoris strain BG10, with the addition 
of 10 % of glycerol and 0.5 M NaCl. Co-factors like NADPH are recruited for the CYP 
dependent reaction by addition of glycerol to the reaction mix. NADPH-regeneration is 
ensured by the activity of metabolic enzymes (Bracco et al. 2013b; Brixius-Anderko et al. 
2015). The substrate was added to a final concentration of 1mg·mL-1 from a 10 mg·mL-1 
stock solution in DMSO. Reactions were incubated at 30°C with shaking at 850rpm. Control 
reactions were carried out in parallel with wild type of P. pastoris strain. Samples for TLC 
analysis were taken after 24 h, extracted twice with 1 mL of ethyl acetate. The organic phase 
was taken for TLC analysis using Polygram Sil G/UV 254 plates (stationary phase), Cer (2 g 
cerium sulfate in 200 mL H2O, 5g Molybdatophosphoric acid and 16mL concentrated  
H2SO4) for staining and a mixture of cyclohexane, ethyl acetate, acetic acid (7:3:0.1, v/v/v) as 
mobile phase. 
6.8.3  In vitro biocatalysis with arginine kinase 
Biocatalysis with the arginine kinase enzyme was in general performed in 30 mL water 
containing 1000 mg of L-arginine, adjusted to pH 8.0 with 0.1 M acetic acid (55mL) and the 
pH again adjusted to 8.0. As to the L-arginine, which was adjusted to pH 8.0, MgCl2 (345 mg 
Magnesium chloride), ATP(158 mg ATP (0.05 equivalents)) and PEP (1124 mg PEP (0.95 
equivalents)) were added. The pH increased to 8.6 and had to be readjusted to pH 8.0 before 
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adding the kinases. Then pyruvate kinase (200 U) and arginine kinase solution (200 mL) were 
added, and the reaction mixture was again adjusted to pH 8 by addition of a small amount of 
0.1 M acetic acid with stirring. The reaction progress was monitored by 
31
P-NMR; the 
reaction mixture was concentrated after two days and dried. 
6.8.4  In vitro biocatalysis with shikimate kinase  
Biocatalysis with the shikimate kinase was performed in 900mL scale. To a solution of 4.6 g 
(26.4 mmol) shikimic acid in 90 mL H2O 3.4 g KCl, 1.9 g MgCl2-hydrate, 4.9 g 
phosphoenolpyruvate (PEP) and 0.47 g ATP were added and the resulting solution was then 
adjusted to pH 7 with 1 M NaOH. To this mixture, 900 units of pyruvate kinase and 900 mL 
of the soluble protein fraction of recombinant shikimate kinase AroL were added. After 18 h 
of stirring at room temperature, NMR analysis of a sample of the reaction mixture showed 
complete consumption of PEP. 
6.8.5  In vitro biocatalysis with argininosuccinate lyase 
Biocatalysis with the argininosuccinate lyase was performed in 100 mL of H2O containing a 
mixture of 5 mmol L-arginine and fumaric acid.The pH was adjusted to 7.5 with 1 M LiOH. 
500 µL of the soluble fraction of the E. coli purified cell extract were added to this solution, 
overexpressing  recombinant argininosuccinate lyase (Arg4). The solution was stirred at room 
temperature and the progress of the reaction was monitored periodically by 
1
H-NMR and 
TLC. 
  
Methods 
130 
6.9 Analytics 
6.9.1 OleP 
Samples (1mL) were extracted twice with 1mL of ethyl acetate. The combined organic phases 
were dried over anhydrous Na2SO4. After complete evaporation of ethyl acetate, the residue 
was dissolved in 200µL of ethanol. Samples (20 µL) were then analyzed using a Hitachi 
LaChrom Elite
®
 HPLC System (Hitachi High-Technologies, Krefeld, Germany) with a Luna
®
 
Omega 5 µm/100Å PS C18 column (Phenomenex, Aschaffenburg, Germany). The mobile 
phase was acetonitrile:water (50:50)% (v/v) containing 0.1% of trifluoroacetic acid. An 
isocratic method (1mL·min-1) was employed at room temperature. The bile acids were 
detected using a LaChrom Elite L-2490 RI Detector (Hitachi High-Technologies, Krefeld, 
Germany). NMR spectra were recorded with a Bruker Avance III HD 600 spectrometer 
equipped with an inverse 
1
H/
13
C/
15
N/
31
P quadruple resonance cryoprobe head and z-field 
gradient (Bruker BioSpin GmbH, Rheinstetten, Germany). Products were dissolved in 
deuterated methanol and the identification was based on 2D-NMR techniques. The 
quantification of the observed products was done by HLC-RI using the by NMR-spectroscopy 
confirmed off white powder resulting from the preparative scale biotransformations of MDCA 
as well as commercially available LCA. Different concentration ranging from 4 mg·mL-1 to 
0.1 mg·mL-1 of MCA and LCA were prepared and measured by HPLC-RI. The resulting 
equation was used to calculate the amount of produced MCA over time. The internal standard 
was used to evaluate the quality of the extraction process. The results of the standard series 
are displayed in appendix Figure A 5, Figure A 6, Figure A 7. 
6.9.2 P450-FG067 
Biotransformation reaction mixtures were extracted twice with ethyl acetate. The organic 
phase was dried under vacuum. Samples were derivatized for GC-MS measurement as 
follows. Part of the crude product was redissolved in 450 µl of MeOH and 10 ul BF3*Et2O 
was added to form the methyl ester. The mixture was heated at 60°C for 45 min. Then MeOH 
was evaporated, 500 µl of CHCl3 and 200 µl of water were added. The phases were mixed 
thoroughly; the chloroform phase was separated and evaporated. The residue was redissolved 
in 300 µl of BSTFA, heated at 80°C for 45 min in order to trimethylsilylate the hydroxy 
functional groups. 
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6.9.3  Arginine kinase 
345 mg of magnesium chloride, 158 mg of ATP (0.05 equivalents) and 1124 mg of PEP (0.95 
equivalents) were added to a solution of 1000 mg of L-arginine in 30 mL of water, adjusted to 
pH 8.0 with 0.1 M acetic acid (55 mL). The pH was again adjusted to 8.0. As to the L-
arginine, which was also adjusted to pH 8.0, MgCl2, ATP and PEP were added, the pH 
increased to 8.6 and had to be readjusted to pH 8.0 before adding the kinases. Then pyruvate 
kinase (200 U) and arginine kinase solution (200 mL, see above) were added and the reaction 
mixture was again adjusted to pH 8 by addition of a small amount of 0.1 M acetic acid with 
stirring. The reaction progress was monitored by 
31
P-NMR, and the reaction mixture was 
concentrated after 2 days and dried.The product was worked up by normal phase (NP) column 
chromatography on silica gel (methanol/water1:1). The strong acidic ion exchanger Dowex 50 
WX8 was loaded with LiOH, then washed again until neutral and the product was 
subsequently converted to the lithium salt, yielding 410 mg (28%) of Nω-phospho-L-arginine. 
Analytical data: Single spot on TLC (silica gel, Rf=0.67 with eluent H2O/1-Propa-nol/NH4OH 
25% =11:6:3; Rf=0.05 with eluent 1-Propanol/NH4OH 25%/ H2O=6:3:1); 
1
H-NMR (D2O, 
400 MHz): δ = 3.45 (dd, 1H, J1,J2 ~ 6 Hz), 3.17 (t, 2H, J = 6.8 Hz), 1.82 (m, 2H), 1.60 ppm 
(m, 2H); 
31
P-NMR (D2O, 162 MHz, CPD): δ = 3.26 ppm. 
6.9.4 Shikimate kinase 
To a solution of shikimic acid (4.6 g, 26.4 mmol)  in H2O (90 mL) KCl (3.4 g), MgCl2-
hydrate (1.9 g), phosphoenolpyruvate (PEP) (4.9 g), and ATP (0.47 g) were added and the 
resulting solution then was adjusted to pH 7 with 1 M aqueous NaOH. Pyruvate kinase (900 
units) and the soluble protein fraction of recombinant shikimate kinase AroL (900 mL)  were 
added to this mixture. After 18 h stirring at room temperature, NMR analysis of a sample of 
the reaction mixture showed complete consumption of PEP. The mixture was then adjusted to 
pH 4 with 1 M aqueous HCl and microfiltrated after 1 h. While stirring a solution of calcium 
acetate (23 g) in  H2O (100mL) was added to the filtrate. Then acetone (400 mL) was added 
slowly. After 2 h, the suspension was filtrated, the residue dried at room temperature on high 
vacuum and taken up in H2O (200 mL). A cation exchanger (Dowex) in its H
+
-form (50 g) 
was added with stirring to this suspension. After 1/2 h, the resulting thin suspension was 
passed through a column with 250 g of the same ion exchanger, the eluate partially 
concentrated on a rotary evaporator and was transformed to the lithium salt by addition of an 
appropriate amount of 1 M LiOH to adjust to pH 7. It resulted in 3.83 g (53% yield) of a 
white solid after lyophilization. Analytical data for the final isolated shikimic acid 3-
phosphate lithium salt: 
1
H-NMR (D2O, 400 MHz, δ): 6.36 (m, 1H, H(2)), ~4.7 (m, 1H, H(3), 
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covered by HDO signal), 3.95 (m, 1H, H(5)), 3,69 (dd, 1H, H(4)), 2.60 (dd, 1H, H(6)), 2.08 
(dd, 1H, H(6’)) 31P-NMR (D2O, 162 MHz, proton decoupled, δ): 4.32; 13C-NMR (D2O, 101 
MHz, proton decoupled, 31P coupled, δ):175.4(s), 135.3 (s), 130.6 (d), 71.4(d), 69.2 (d), 67.3 
(s), 31.9(s). Purity by TLC (silica gel 60 on glass plates, n-propanol/H2O/AcOH = 6:3:1), Rf 
(shikimic acid) 0.85, and Rf (shikimic acid 3-phosphate) 0.72. Purity by HPLC: >97%. 
6.9.5 Argininosuccinate Lyase 
A mixture of L-arginine (876 mg, 5 mmol) and fumaric acid (89 mg, 5 mmol) in H2O (100 
mL) was adjusted to pH 7.5 with 1 M aqueous LiOH. A soluble fraction of the purified cell 
extract of E. coli overexpressing recombinant argininosuccinate lyase (Arg4) (500 µL) was 
added to this solution. The solution was stirred at room temperature and the progress of the 
reaction was monitored periodically by 
1
H-NMR and TLC (silica plates with n-propanol : 
H2O = 2:1 as a solvent and detection by ninhydrin and by exposing to short wave UV-light at 
254 nm. After the conversion was ceased (6 days), the mixture was concentrated on a rotary 
evaporator at high vacuum and room temperature, giving a white solid. This was dissolved in 
H2O (5 mL) and then n-propanol (10 mL) was added. The resulting emulsion was flash-
chromatographed on silica with n-propanol:H2O = 2:1. The early fractions contained 
unreacted fumarate followed by the L-argininosuccinate in later fractions. Fractions 
containing the product L-argininosuccinate were pooled, filtered, frozen and lyophilised to 
give 1.07 g (~70%) of the pure product N-(([(4S)-4-amino-4-carboxy-butyl]amino)-
iminomethyl)-L-aspartic acid lithium salt (L-argininosuccinic acid lithium salt) in the form of 
a colorless solid. Analytical data for N-(([(4S)-4-amino-4-carboxy-butyl]amino) imino-
methyl)-L-aspartic acid lithium salt (L-Argininosuccinic acid mono-lithium salt) 
NMR: δH (400 MHz; D2O) 4.14 (1H, dd, J1 3.4, J2 9.9, succinyl–CH–NH), 3.65 (1H, dd, J1 = 
J2 6.2, arginyl-CαH), 3.17 (2H, t, J 6.8, arginyl-CδH2), 2.71 (1H, dd, J1 3.4, J2 16.1, 
succinyl-CH), 2.41 (1H, dd, J1 9.9, J2 16.1, succinyl-CH´), 1.80 (2H, m, arginyl-CbH2), 1.58 
(2H, m, arginyl-CgH2); dC (100.6 MHz; D2O) 178.9, 177.1, 174.4 (3 COOH), 155.8 
(guanidino-C), 55.1, 54.3 (2 NH2–C–COOH), 40.6 (succinyl-CH2 and arginyl-Cd), 27.6 
(arginyl-Cb), 23.9 (arginyl-Cg). H2O content (Karl Fischer titration): 14.1% elemental 
analysis, found: C, 33.3; H, 6.2; N, 15.5%. Calcu-lated for C10H16N4O6Li2. 14.1% H2O: C, 
35.2; H, 6.2; N 16.4%; TLC, purity: 95.1% (n-propanol:NH4OH(25%):H2O = 6:3:1; 
ninhydrin; Rf 0.4); qNMR, content: 94.4% (calculated as di-lithium salt including 14.1% 
H2O). 
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6.10 Bioinformatic methods 
6.10.1 Used software 
Table 34: List of used important software 
 
 
Software Purpose Developer 
Chem Draw 12.0 
Creation of chemical 
molecule structures and 
reaction schemes 
Cambridge Soft 
Geneious 
Construction of primers and 
virtual cloning, DNA 
sequence analysis and 
management 
Biomatters, Ltd 
Snapgene 
Construction of primers and 
virtual cloning, DNA 
sequence analysis and 
management 
GSL Biotech LLC 
GelAnalyzer Freeware 
1D gel electrophoresis image 
analysis software 
GelAnalyzer 
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Appendix 
7.1 CYP107D1 
Table A 1: Substrate scope of P450 monooxygenase OleP 
Steroids and fatty acids tested in this study as substrates for CYP107D1. Twenty two steroids were screened 
using the whole-cell biotransformation, out of which two (LCA and DCA) were investigated further.  
 
No Substrate Conversion 
1 Testosterone + 
2 Androstendione - 
3 Progesterone - 
4 Dehydroepiandrosterone - 
5 7-Dehydrocholesterol - 
6 Cholesterol - 
7 β-Sitosterol - 
8 Cortisone - 
9 Corticosterone - 
10 4,5α-Dihydrotestosterone, - 
11 Androstanolone - 
12 Stanolone - 
13 DCA (Deoxycholic acid) + 
14 LCA (Lithocholic acid) + 
15 Chenodeoxycholic acid (CDCA) - 
16 Ursodeoxycholic acid (UDCA) - 
17 iso_LCA (3α-hydroxy-5α-cholan-24-oic acid) - 
18 Hyodeoxycholic acid (HDCA) - 
19 Chlorzoxazone - 
20 Canrenone - 
21 Daidzein - 
22 dexamethasone - 
23 C10 Decanoic acid (capric acid) - 
24 C12 Lauric - 
25 C14 Myristic acid - 
26 C16 Palmitic acid - 
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Figure A. 1: 2D-NMR of the purified MCA (3α,6β-dihydroxy-5β-cholan-24-oic acid) 3α,6β-dihydroxy-5β-
cholan-24-oic acid. [M
-
]: 391.5; 
1
H-NMR δ (ppm, MeOD): 0.72 (s, 18-Me), 1.10 (s, 19-Me), 3.51 (tt, J=4.7, 
11Hz, 3-H), 3.69 (H-6); 
13
C-NMR δ (ppm, MeOD): 12.6 (C-18), 26.16 (C-19), 72.1 (C-3), 74.04 (C-6). 
 
Figure A. 2: MS verification of MCA (Grobe et al. 2020).  
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Figure A. 3: 2D NMR of the purified 3α,6β,12α-trihydroxy-5β-cholan-24-oic acid. 3α,6β,12α-trihydroxy-5b-
cholan-24-oic acid. [M
-
]: 407.4; 1H-NMR δ (ppm, MeOD): 0.74 (s, 18-Me), 1.09 (s, 19-Me), 3.50 (tt, J=4.7, 
11Hz, 3-H), 3.69 (q, J=2.60Hz, H-6), 3.98 (t, J=2.70Hz, H-12); 13C-NMR δ (ppm, MeOD): 13.80 (C-18), 26.40 
(C-19), 72.83 (C-3), 74.55 (C-6), 74.60 (C-12).(Grobe et al. 2020)  
 
 
Figure A. 4: MS verification of 3α,6β,12α-trihydroxy-5β-cholan-24-oic acid (Grobe et al. 2020). 
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Figure A. 5: HPLC-RI chromatograms of E. coli C43 (DE3) pET-28a oleP, pACYC pdR/pdX (black) and E. coli 
C43 (DE3) pACYC pdR/pdX (grey) are overlayed. Peaks marked with numbers 1 correspond to MCA, 2 
corresponds to the internal standard used CDCA and 3 corresponds to LCA (Grobe et al. 2020). 
 
Figure A. 6.: Product quantification of MDCA based on HPLC-RI measurements(Grobe et al. 2020). 
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Figure A. 7: Substrate quantification of LCA based on HPLC-RI measurements (Grobe et al. 2020). 
7.2 P450_FG067 
 
Figure A. 8: Strategy of subcloning P450-FG067 from pUC vector to the pET24 vector, contains a kanamycin 
resistance gene, an IPTG inducible promoter system. 
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. 
 
Figure A. 9: PCR amplification of P450-FG067.Amplicons are shown on a 1% agarose gel corresponding to: (1) 
marker lanes containing a 1 kb ladder (Thermo). (8) P450 –FG067 positive control, (9-12) PCR products with 
the expected sizes in kb for PCR products 3330 bp. 
 
 
Figure A. 10: PCR control to monitor the integrity of P450-FG067 amplicons in PET24a vector.PCR products 
are shown on a 1% agarose gel corresponding to: (1) marker lanes containing a 1 kb ladder (Thermo). (8) P450 –
FG067 positive control (PUC-FG0067), (9-12) PCR products with the expected sizes in kb for PCR products 
3330 bp. 
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Figure A. 11: MS verificationof hydroxylated C10 fatty acids after derivatization 
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Figure A. 12. MS verification of of hydroxylated C12 fatty acids after derivatization  
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Figure A. 13: MS verificationof of hydroxylated C14 fatty acids after derivatization 
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Figure A. 14. MS verificationof of hydroxylated C16 fatty acids after derivatization 
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